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This paper is about a specific type of Knowledge Intensive Business Services (KIBS), namely R&D 
services in biotechnology, and their growth in four Latin American countries: Argentina, Brazil, Chile 
and Uruguay. Like other emerging and developing countries, the four countries in the Southern Cone 
are slowly adopting biotechnology. Well over a hundred dedicated biotechnology firms are already 
providing services in the region, from R&D to bioinformatics, to gene identification and stem cell 
databank storage services.  We interviewed some 23 firms in the region, as well as a few policy 
makers and other public servants, we analyzed the policy environment, conducted the analysis of the 
data and linked them with the theoretical framework and hypotheses. 
 
The paper starts with a theoretical discussion about KIBS, draws a few hypotheses, then presents the 
survey and its methodology, the science, technology and innovation (STI) policy framework in the 
region, and concludes by proposing several policy additions for science and technology: increasing 
public R&D expenditures, designing and implementing venture capital, academic recruitment and 
procurement innovation policies, in order to increase the supply and demand of biotechnology 
services. Finally, the quality and quantity of biotechnology statistics (and all R&D statistics) need to 
be seriously reconsidered and revamped. External advice (i.e. from OECD and/or Statistics Canada), 
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1. Theory and hypotheses: innovation in Knowledge Intensive Business Services 
Most of the theory and empirical studies on innovation has focused on innovation in the production of 
goods, mostly in manufacturing. However, the service sector has become most important in terms of 
employment and production; in addition, it is increasingly seen as a major factor in R&D and 
innovation (Gallouj and Savona, 2009). This is particularly so in such innovation intensive sectors as 
computer software, and R&D services like biotechnology, nanotechnology, and clinical research, to 
name a few. Not all Knowledge Intensive Business Services (KIBS) are innovation intensive. We can 
see a clear spectrum in terms of innovativeness. Some, such as accountancy services are at the low 
side of the spectrum. R&D services are at the other extreme. Engineering services lie in the middle. 
This paper is about the most innovation intensive services: R&D services. 
Whatever the specific sub-domain, the quantitative analysis of innovation in services – particularly on 
the side of the outputs – poses several serious problems as Griliches (1992) underlined. 
- What is exactly sold? The knowledge produced by the R&D services firm? Is it a prototype in 
the case of the software program? The installation of the software in the clients’ hardware? The 
plan of the new car or building, in the case of a design or engineering firm? 
- What is the role of the user? Up to a certain degree, the user participates in the definition of the 
service, thus in the framing of the service innovation itself. When a pharmaceutical firm 
requests R&D services from a dedicated biotechnology firm (DBF) it is clear that the large 
corporation is participating in the innovation it requests from the smaller service firm. 
- The quality of the service is more difficult to measure. This is a clear problem in the analysis 
of education or health services, and in R&D services. The client itself may not have a clear 
understanding of the quality of the services he/she is buying. 
Today we may add some other conceptual and measurement problems. The innovation produced by 
the service firm may have large positive productivity impacts on the users of the innovation, be they 
agricultural farms using new genetically modified organisms (GMOS), pharmaceutical corporations 
using new knowledge produced by a human health R&D services firm, or a manufacturing company 
using a new piece of software. On a second line of users, the R&D knowledge can generate positive 
impacts on the balance of payments through the export of the new products and services, and other 
even more remote positive impacts on the increased life expectancy of the population through better 
access to food and medicines. Under these conditions, it becomes more difficult to measure the 
impacts of service innovation (Pilat, 2001). 
Other issues are also relevant. KIBS are often produced within networks, involving not only the 
service producer and its client, but also other knowledge producing institutions such as government 
laboratories, universities and other R&D active firms. The efficiency and effectiveness of the KIBS 
firm depends up to a certain point on the size, and the resources it can find in its environment. The 
issues of open innovation are relevant at this point. 
In addition, public institutions and policy incentives compose a good part of the environment of the 
KIBS firm. The quantity and quality of policy incentives, public institutions and regulations will affect 
the nature and quality of the services produced by the KIBS firm. 
Muller and Zenker (2011) have shown that KIBS not only depend on the quality and quantity of public 
policies and incentives at the national and regional levels; they are a key component of these national 
and regional innovation systems. In the same direction, Pilat (2001) suggests that KIBS are a second 
knowledge infrastructure, one that complements the public one of universities and public laboratories. 
Several authors have found that in OECD countries, these KIBS experience very rapid growth, and 
they are among the fastest growing sectors of the economy (Pilat, 2001; Mueller and Zenker, 2001). 
Yet, drivers of growth in these KIBS are not confined to public policy and incentives. The size and the 
 
  3 
 
nature of the market for these services are very important determinants of KIBS innovation (Miles, 
2005). It may be the case that agricultural countries have a market for some types of agricultural 
biotechnology, yet policy regulations (i.e. policy restrictions to field tests or commercial uses of 
GMOS) will set limits to the size of those markets. 
Policy incentives for innovation and policy evaluation have been built over the years with 
manufacturing innovation in mind. Innovation in computer software and related services or in R&D 
business services is too often neglected both in policy and in statistical offices.  
Under these considerations, the two general hypotheses of this work become clearer and well justified. 
Hypothesis 1: Innovation (including innovation in services, and particularly KIBS) generates positive 
impacts in the economy 
Hypothesis 2: Public support activities have positive impacts on innovation in services and 
particularly on KIBS. Public incentives to R&D and innovation, but also public regulations of 
different kinds may represent positive factors but also barriers to innovation.  
To these general hypotheses we may add a few others.  
Hypothesis 3: KIBS are major components of national and regional innovation systems, as their 
positive impacts occur at many different layers of the economy.  
Hypothesis 4: The size and regulation of the markets represent drivers (and eventually obstacles) to 
innovation in KIBS. 
Innovation in KIBS 
Several authors distinguish between traditional professional services (p-KIBS) such as accountancy, 
advertising and legal services, and technology based KIBS (t-KIBS) such as computer software, R&D 
services and engineering consultancy. The former are not innovation intensive, the latter are very 
much so (Freel, 2005). Table 1a and Table 1b show the main types of KIBS in their industrial 
classification codes. 
Table 1a: Industrial classification of KIBS in the Mercosur 
Actividades profesionales, científicas y técnicas 
69 Actividades jurídicas y de contabilidad 
70 Actividades de las oficinas centrales y consultoría de gestión empresarial 
71 Servicios de arquitectura e ingeniería  
72 Investigación y desarrollo 
73 Publicidad e investigación de mercados 
74 Otras actividades profesionales, científicas y técnicas 
 
Table 1b: Industrial classification of KIBS in North America 
54 Professional, scientific and technical services 
5411 Legal services 
5412 Accounting, tax preparation, bookkeeping and payroll services  
5413 Architectural, engineering and related services  
5414 Specialized design services  
5415 Computer design and related services  
5416 Management, scientific and technical consulting services  
5417 Scientific research and development services  
5418 Advertising, public relations and related services  
5419  Other professional, scientific and technical services 
Source: Statistics Canada: North American Industry Classification System Canada (NAICS), 2012. 
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2. Sector context: Biotechnology and its international diffusion 
Biotechnology is not an industry but a set of general purpose technologies applied to many industries 
such as agriculture, environmental remediation services, food, mining, pharmaceuticals, and other 
industrial activities (OECD, 2009).  
 
2.1 The birth of biotechnology 
Modern biotechnology was born in the early 1950s, when James Watson, Francis Crick and Maurice 
Wilkins discovered the structure of DNA at Cambridge, United Kingdom (UK). Other major landmark 
events were the development of technologies to conduct genetic engineering in 1973 by Herbert Boyer 
and Stanley Cohen, respectively at the University of California, in San Francisco and at Stanford 
University. Again in Cambridge, UK, Cesar Milstein and his postdoctoral fellow, George Köhler, 
developed hybridoma techniques to produce monoclonal antibodies used to fight cancer, among other 
diseases. Many other scientific and technological developments followed, and biotechnology came to 
be able to genetically modify microorganisms, plants and animals to produce such human proteins as 
insulin, human growth hormones, interferon and interleukins, as well as monoclonal antibodies. In the 
area of agriculture, biotechnology was used to produce genetically modified organisms (GMO), thus 
increasing productivity and introducing plants resistant to pests, drought, and contaminated soils. 
Lands unsuitable for agriculture became productive. In mining, biotechnology was used to produce 
bacteria that assist mining companies to leach out minerals from ores. In environmental remediation, 
microorganisms are used to treat waste and contaminated water. Genetically modified plants are used 
to decontaminate lands containing large amounts of minerals. Gene identification techniques are used 
for a large variety of applications including those in the pharmaceutical industry, but also, in legal 
suits and criminal identification, and animal and plant reproduction. In the near future, gene therapy 
will introduce a whole new set of therapeutic possibilities. 
 
2.2 The international diffusion of biotechnology 
Biotechnology as a science was born in the United Kingdom and the United States (USA), but its 
commercial applications were first developed in the USA. The first commercial biotechnology firm, 
Genentech, was established in 1976 in California by venture capitalist Robert Swanson and biochemist 
Herbert Boyer. In the following years thousands of dedicated biotechnology firms were founded in the 
United States, Western Europe, Canada, Japan and elsewhere. In OECD countries, they were funded 
by government subsidies at first and by venture capital afterwards (Kenney, 1986). Most of the 
products and services invented by these companies require major funding and skills in order to be 
developed. DBF specialized in human health products allied with large pharmaceutical corporations to 
obtain approval and market them. DBF specialized in new seeds often gave licenses to large grain 
traders such as Monsanto and Syngenta. Biotechnology firms cooperated with mineral corporations to 
produce new genetically modified bacteria. Some types of service firms, though, remained 
independent for reasons we will examine later. 
 
In biotechnology, the underlying science base evolves very fast and major breakthroughs open new 
commercial opportunities for small and medium-sized enterprises (SME). Thus, in 2003 the 
sequencing of the human genome allowed the creation of a new area of biotechnology (genomics). 
Using this information and technology, small and medium-sized dedicated biotechnology firms (DBF) 
could remain independent and offer gene-sequencing services to pharmaceutical corporations, farms, 
governments and individuals. The very large number of documents (millions of patents, scientific 
publications and approval applications) supported the growth of bioinformatics, a service industry that 
retrieves, stores and analyses the millions of pieces of genetic information stemming from the use of 
increasingly powerful and rapid sequencing equipment. Bioinformatics also analyses information 
about collateral effects of drugs, information that rapidly leads to the discovery of new medicines.  
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Genomics was followed by proteomics, the study of thousands of proteins that are produced by 
organisms. Proteomics also deals with protein purification and mass spectrometry. New companies 
specializing in this new discipline were created. 
 
The United States remains the leader in scientific publication and commercial application of 
biotechnology. Australia, Canada, Israel, Europe and Japan are striving to catch up with the leader 
(Niosi, 2011). A series of emerging countries in Africa, Asia, and Latin America are entering the fray 
(Niosi et al, 2012). They include Argentina, Brazil, China, India, Mexico, Singapore, South Africa and 
South Korea. Their publication patterns show that their scientific base is catching up, but they seem to 
lack adequate complementary institutions, such as public and private venture capital organizations and 
public policy incentives, that would allow them to catch up in commercial biotechnology. 
 
2.3  Biotechnology business models 
The literature on biotechnology business models has become fairly abundant in the last years (Casper, 
2000; McKelvey, 2008; Konde, 2009; Rasmussen, 2010).  
 
“A business model is a way to create value for a business and then at least to capture some of that 
value for the organization” (Chessbrough, 2011, p. 90). Generally speaking, two major business 
models are recognized among dedicated biotechnology firms: the product and the service models. In 
the product business model, the DBF conducts R&D services in order to create a new or improved 
product such as a medicine, a diagnostic kit, a tool, or a GMO. Its goal is either to sell it directly to the 
market or, more often, to license out the new technology to a larger corporation that is able to obtain 
approval for the product, and is able to manufacture it on a large scale and market it internationally. 
The product business model requires large investments, involves extensive project costs and risks, and 
is scarcely adapted to DBF in developing countries. 
 
The service model, on the other hand, is based on a platform technology that allows the company to 
deliver services to a variety of different clients. Bioinformatics and gene identification are among two 
of the most common business service models among dedicated biotechnology firms. Compared to the 
product model, the main advantage of the service model is that it requires a smaller initial investment, 
and generates returns much faster. Service approvals are quicker or not required, while biotechnology 
product approval is a lengthy and costly process. For these reason, some companies adopt “hybrid” 
business models, providing services to produce income in a short period of time and developing 
products on a longer timeframe. 
 
Several authors have examined the stability of all types of biotechnology business models (Pisano, 
2006; Rasmussen, 2010). The sustainability of the companies adopting the first business model 
depends on their capacity to continuously generate new products. The sustainability of the service 
firms, on the other hand, depends not only on their ability to innovate, but also on their ability to 
generate processes that allow them to gain market share on the basis of decreasing costs and prices. If 
and where these increasing returns processes are not set up, competition would bring profits down, as 
the firm’s services can be imitated much faster than in the product model. 
 
In biotechnology services, company turnover is lower than in other types of service SMEs. Yet, both 
types of dedicated biotechnology companies sometimes disappear either because they are successful 
and able to repeatedly generate new products and are acquired by larger firms (this was the case for 
Biochem Pharma, Chiron, Human Genome, Medimmune, Serono and others), or because they are 
unable to repeat the success of their first discoveries, and run out of funds. In bioinformatics, 
competition and imitation have sometimes destroyed leading firms (Rasmussen, 2010). 
 
In Latin America, as in Europe, North America, China and India, generic pharmaceutical corporations 
are adopting biotechnology most often through the acquisition of DBF operating in human and animal 
health R&D. Acquisition has been a fast and cost-effective method of incorporating skilled personnel 
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and technologies in order to compete in the expanding biosimilar market. Larger firms are acquiring 
all types of biotechnology firms in order to widen their offer of products and services.  Yet the 
dynamic evolution of the underlying science continuously allows the production of new goods and 
services aimed at different markets. 
 
2.4  Policy incentives 
Because the underlying science base is highly dynamic and increasingly costly, biotechnology requires 
strong government incentives and support. It also creates many goods, services and products such as 
new medicines, new seeds, key genetic information and environmental services.  
 
There are few figures regarding the public funds spent on biotechnology in different countries. The 
reason is that many countries do not publish information at the company or sector level about tax 
credits, direct subsidies or other public funding for R&D. Reid and Ramani (2012) published figures 
collected from the OECD, showing that in 2005 the United States was leading the world with 23.2 
US$ billion in public support, followed by Japan with $1.9 billion, Korea with $1.2 billion, Canada 
and Singapore with $0.6 billion, China with $0.5 billion, and India with $0.2 billion. For 2009, the 
OECD (2011) put Germany at $7.6 billion, Korea at $2 billion, Spain at $1.3 billion, Russia at $760 
million and Canada at $724 million1. These figures show that the biotechnology sector is far from 
being inexpensive for the public purse, and that the design of policy incentives is crucial if such large 
amounts are to be followed by economic results. 
 
Because biotechnology has had a great impact on many different industries, most notably agriculture 
and pharmaceuticals, OECD governments have used a large variety of incentives to nurture the 
creation and growth of these firms. They include academic research grants, public venture capital and 
public incentives for the development of private venture capital, direct subsidies to SBF, tax credits for 
R&D, public R&D laboratories and others (Niosi and Bas, 2004). 
 
The design, implementation, assessment and fine-tuning of these incentives requires a permanent, 
sophisticated, meritocratic and professional bureaucracy. Most OECD countries have had for decades, 
or longer, this type of professional public service. In Latin America, this is a necessary structure to be 
completed in the future; the link between economic development and professional public services has 
been well established (Evans and Rauch, 1999). 
 
At this time, it is important to underline the fact that other developing and newly industrialized 
countries are also vying to enter this industry. Since the late 1990s, Singapore has focused on the 
biomedical sciences. For this purpose it built a seven- building, 18.5 hectare, 300 million US$ 
complex called Biopolis, and invited foreign biotechnology and pharmaceutical firms to build R&D 
laboratories in the cluster. It also created a series of large public laboratories such as the Institute for 
Molecular and Cell Biology, the Bioinformatics Institute and the Bioprocessing Technology Institute, 
which are part of the cluster. Over 5000 researchers work in the area, and private and public 
expenditure is in excess of 800 US$ billion annually. Paying high salaries, Singapore has been able to 
attract top scholars from around the world and increasing the human capital pool in the sector. Another 
formerly poor country, South Korea, has decided to enter biotechnology through another set of 
incentives. In 1994, the government of South Korea decided to make biotechnology its next rapid 
growing sector. From 2000 to 2007, the South Korean government invested over 4.4 US$ billion in the 
field. Also, the government created a Korean Food and Drug Administration (KFDA) modelled on the 
US FDA, with the goal of entering the US and EU biotechnology markets with high-quality products 
and services. A late entrant in biotechnology, by 2010 South Korea had some 900 DBFs, mostly SMEs 
(OECD, 2011). Total biotechnology expenditure in the country was over 1 US$ billion. 
 
                                               
1 All figures are in millions, current US dollars at PPP. 
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In China and India as well government support has helped to create a vibrant set of DBFs.  Strong 
government support – particularly strong in China – contributed to rapid economic growth and 
demand for biotechnology goods and services. In China, the national and the provincial governments 
fund biotechnology. At the national level, funding involves different ministries and agencies such as 
the Ministry for Science and Technology, the Ministry of Agriculture, and the Ministry of Health 
(OECD, 2008). In order to accelerate learning, China has invited large MNCs to set up R&D labs in 
China, out of which new DBFs will spin off.  
 
2.5  Government regulation 
In biotechnologies, government regulation is a major determinant of the contours and the strength of 
the industries that apply these technologies. These include: 
- Patenting: what can be patented, how long is the exclusivity conferred by the patent to the 
applicant. 
- Health and food; what transgenic crops and animals can be accepted for human consumption 
and how are the new biopharmaceutical drugs be authorised in the domestic market. 
- Environment: under what conditions are new plant varieties, bacteria or animal can be released 
in the environment 
- Trade: what principles frame international trade in biopharmaceutical drugs, GMOs and 
microorganisms. 
Because the United States has taken the lead in all these technologies, it has also be the first one to 
implement regulation on new products stemming from these technologies. As such, the United States 
has an advantage of potentially framing the regulation of the different industries adopting these 
biotechnologies. However, this priority does not mean that US regulations are the universal best 
practices that backward countries have to adopt blindly. An example will suffice to illustrate the point. 
Most new transgenic plants and biopharmaceutical drugs have been invented in the United States; as 
such this country is the most reluctant to share its technology with other less advanced countries, and 
open its trade to biological comparable drugs or crops produced elsewhere. “Elsewhere” includes the 
European Union, Japan, South Korea, India, Israel, China or Latin America. The United States 
protects their technological advance through different means. Backward countries need to implement 
different policies in order to catch up with the global leader. 
2.6 Regional concentration and biotechnology clusters 
Like other technology based KIBS, biotechnology activities and firms are strongly concentrated in 
large metropolitan areas where research universities and government R&D institutes are located 
(Swann et al, 1998). In addition, venture capital tends also to be located close to these research 
universities that spun-off large numbers of technology based firms. In the United States, San 
Francisco, Boston, New York, and Los Angeles concentrate a large proportion of dedicated 
biotechnology firms (Romanelli and Feldman, 2006). Similarly, in Canada, Montreal, Toronto and 
Vancouver are they key centres of biotechnology innovation (Niosi, 2005). In the United Kingdom, 
Cambridge, London, Oxford concentrate the largest numbers of British biotechnology firms (Shohet, 
1008). 
2.7 Skilled human capital and star scientists 
Lynn Zucker and her team at the University of California Los Angeles found that US biotechnology 
firms tend to be created by star scientists (those that appear as inventors in a large number of patents 
and as authors in a large number of patents (Zucker et al, 1998; Zucker and Darby, 2007). The same 
conclusion was found in Japan (Darby and Zucker, 2001) and in Canada (Niosi and Queenton, 2010). 
This fact is due to the fact that the production of knowledge is highly skewed, and a small number of 
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scientists are responsible for a large number of inventions. In addition, venture capitalists tend to 
follow the activities of these stars and fund the companies in which these scientists are working or 
have founded. 
2.8  Innovation in biotechnology services 
The innovation activities of dedicated biotechnology firms are basically R&D activities. They include 
process innovation (how to produce new GMOs, new medicines through genetic engineering, genomic 
analysis and the like), and product innovation (new or improved GMOs, drugs, or services such as 
gene identification, bioinformatics software or other). New-to-the world products and processes are 
almost entirely created in rich advanced OECD countries.  
In biotechnology, open and flexible innovation is almost mandatory. The rapid additions to the 
scientific and technological knowledge, from genetic engineering to genomics and proteomics, make 
that no university, public laboratory or private company, no matter their size or resources, can store 
and use all the information available. Alliances and cooperation are overwhelming in biotechnology 
(Baum et al., 2000; Niosi, 2003). Both dedicated biotechnology firms and large industrial corporations 
conduct R&D in collaboration with other firms. 
2.9 Conclusion 
Biotechnology is a science-based set of technologies used in many different industries. In the R&D 
service sector, SMEs represent the vast majority of firms using these technologies. Dedicated 
biotechnology firms, classified as R&D service companies, tend to cluster in large metropolitan areas 
and around research universities, in order to get close relationship to institutions where new 
knowledge is generated. Over the last three and a half decades they have adopted several business 
models. One finds similar models in both advanced OECD countries and emerging countries. If the 
sums invested by DBF and governments in OECD and Latin American countries are fairly different, 
the modus operandi of these firms is quite comparable, and the models present similar advantages and 
disadvantages in both groups of countries. 
  
 




In a nutshell, the study was done through the identification of suitable DBFs using modern 
biotechnology, conducting interviews with company executives and government and incubator 
officials using a proven questionnaire. 
 
3.1 Population and samples 
 
The number and distribution of dedicated biotechnology firms in each Latin American country is not 
exactly known. Estimations vary widely from one author to the next. The reason is that no statistical 
office in the region studies the R&D services sector, and individual researchers using different 
methods and definitions to make their own estimations. 
 
Fortunately, several sources have nominal lists of companies. The most reliable one is Biotecsur, the 
organization of biotechnology-active companies in the region. In a previous study on biotechnology in 
developing countries (Niosi, et al, 2012) we had found the same problem, and used the same solution: 
to build a list of companies using different sources, companies that can be considered DBFs and 
request interviews with them. The company questionnaire (see Annex 1), built on the basis of 
Statistics Canada one, solves the problem of identifying DBFs from other biology-using firms, as one 
of the main and first questions asks what modern biotechnologies the company uses. In a few minutes 
the interviewer knows whether he/she is visiting a modern biotechnology firm or not. Our samples, 
yet, have no pretension to be representative ones. But the companies we have interviewed are modern 
dedicated biotechnology firms. 
 
Whatever the source, it was clear that biotechnology companies are located in the largest 
agglomerations in each Latin American country: Buenos Aires and Rosario in Argentina, Belo 
Horizonte, Sao Paulo, and Rio de Janeiro in Brazil, Santiago in Chile and Montevideo in Uruguay. In 
this sense, the localization patterns closely resemble those in advanced OECD countries. 
 
As to policymakers, in each of these countries several government departments have a say on the 
development of biotechnology. They include the Ministries of Agriculture, Education, Environment, 
Health, and Industry, and independent regulatory agencies such as ANMAT in Argentina and 
ANVISA in Brazil. In addition, in federal countries such as Argentina and Brazil, some provinces 
(states in Brazil) have their own incentives and regulations. Finally, a key component of the incentive 
toolkit are company incubators, usually linked to the large national universities. To interview them all 
would require months of intensive work in the field. We decided to interview a few of them in each 
country, selecting the ones that seem among the most active in biotechnology. Annex 1 gives the 
relevant information on the ones that were selected and accepted to be interviewed. It is clear that the 
information they provided was about the existing programs and the resources invested in them. We 
counted on the executives of the biotechnology firms to give their appraisal of these programs. 
 
3.2 Questionnaires and variables 
The questionnaire used is an adaptation of the one used by Statistics Canada in their bi-annual study 
on biotechnology firms. It contains variables on the technologies used, products and services in the 
markets, R&D and other innovative activities, skilled personnel, employment and sales. It contains 24 
questions that may be converted into over 100 variables. 
 
3.3 Field work 
The interviews were requested well in advance, and most of the companies invited to participate 
accepted, as well as government officials and incubator executives. Dr Bas conducted the interviews in 
Chile in August 2012, and Dr Niosi in Uruguay (June), Brazil (August), and Argentina (September). 
The following insert and Annex 1 (Questionnaires) summarize the fieldwork. 
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Argentina 7 2 1 1 11 
Brazil 9 2 1 1 13 
Chile 4 1 1 0 6 
Uruguay 2 0 1 0 3 
Total 22 5 4 2 33 
 
 
3.4 Descriptive statistics 
 
The majority of the 22 DBFs interviewed were active in human health (15 or 68%), plus three others 
active in human and animal health. In every country except Chile, human health was the most 
common application. Less than half of the interviewed firms (10 or 45%) were university or public 
laboratory spinoffs; the others were start-up firms. The average age was 10 years, and the median age 
was 8,5 years, but the Chilean and Uruguayan firms were much older.  
 
In each country there are one or two firms over 100 employees. The average firm had 50 employees 
and the median number of employees was 22; the average numbers show the impact of some very 
large firms on the mean sizes. Table 2 shows the main statistics. 
 
Table 2: Summary of descriptive statistics 
 
Variable Argentina Brazil Chile Uruguay Total 
Interviewed DB firms 7 9 4 2 22 
Active in human health 4 8 1 2 15 
Active in human & animal health 1 1 1 0 3 
Active in Ag-Bio 2 0 1 0 3 
Active in mining, environment 0 0 1 0 1 
University/public lab spin-off 3 6 0 1 10 
Average age 9 9 14 15 10 
Median age 6 8 11 15 8,5 
Oldest firm 29 16 22 c 29 
Youngest firm 1 3 4 c 1 
Average employment 2011 60 51 54 22 50 
Median employment 2011 12 30 15 c 22 
Average sales 2011 (US$M) 9  0,2 7 0,2 3,2 
Median sales 2011 (US$M) 0,2 0,2 2,5 0,2 0,2 
Firms that exportedin 2011 1 2 3 2 8 
Problems with regulation cost 0 5 0 0 5 
Problems with regulation speed 3 5 0 0 8 
Problems with regulation norm 1 4 1 1 7 
Problems with other regulation  0 4 0 1 5 
Firms using public funds 5 8 2 1 16 
Firms using private funds 7 9 4 2 22 
“Successful” firms* 5 7 3 1 16 
C= confidential 
* Successful means growing firms in terms of employment and /or ssles 
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In 2011, average sales were US$3,2 million, but again, a few large companies biased the averages. 
Over one third (8/22) of the interviewed firms were exporting products and/or services. Not by chance, 
the smaller the country the higher the percentage of companies that export. In Argentina and Brazil, 
firms can survive without exports, counting on the domestic market, not in Chile or Uruguay, were 
exports are mandatory and a condition of survival. 
 
Regulatory problems were fairly abundant. In comparative terms, there were more abundant in Brazil, 
followed by Argentina and Uruguay. Speed and the quality (or the absence of) regulations were the 
most frequent complaints. In each country, though, the more the firms were advanced in the product 
and/or process development, the more they requested authorizations, and the more they found 
difficulties. Very young firms usually do not completed their products or processes, thus did not 
request any authorization. Also, the more complex the product, or the more innovative, the more the 
authorizations took time and the lack or inadequacy of regulations became evident.   
 
Very often companies (72% of them) used public funds, in addition to private funds (100% of them 
did). As to public funds, companies complained about the scarcity of government loans, venture 
capital, or non-reimbursable R&D subsidies. In terms of private funds, in over 50% of the companies, 
managers had invested personal funds, family funds, or had obtained capital or loans from private 
investors. 
 
Over two thirds of the firms (16/22) interviewed were “successful”. By success we mean that they 
grew over the 2007-12 period, usually both in terms of employment and sales. The other companies 
were not, including two in Argentina, two in Brazil, one in Chile and one in Uruguay. Of course 
companies may grow and still be not profitable, and also some may not grow and yet be profitable. 
But we did not ask whether the companies had profits or not, a very sensitive question that is not 
usually responded. 
 
3.5  Innovation indicators 
 
In biotechnology-active companies, R&D is a routine activity. All the companies we visited were 
conducting R&D. Yet the amounts they spent were – on average – very low: US$0,9 million. The 
median amount is even lower: US$ 300,000. Such amounts show that government incentives were 
modest, to say the least, and probably highly skewed: a few firms were obtaining large amounts of 
public support, and most firms obtaining small amounts or no public funds at all. Table 3 presents the 
main innovation statistics of the sample. 
 
Table 3: Innovation statistics 
 
Variable Argentina Brazil Chile Uruguay Total 
Interviewed DB firms 7 9 4 2 22 
University/public lab spin-off 3 6 0 1 10 
Collaboration with universities 7 8 4 1 20 
Collaboration with public labs 7 8 1 0 16 
Cooperation with other firms 5 7 3 2 17 
Average R&D expenditure (US$M) 1.3 1.3 0,11 0,15 0,9 
Median R&D expenditure (US$M) 0.25 1 0,12 c 0,3 
Patenting firms 4 3 2 1 10 
Firms with US, EPO or PCT patents 
(new to the world innovations) 
2 2 1 0 5 
Firms with trademarks 4 4 2 2 12 
Product innovation in the market  
(New to the country) 
6 6 3 2 18 
Process innovation (New to the country) 6 6 3 2 18 
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Open innovation was paramount. Almost all the firms (20/22) collaborated with research universities 
and over two thirds of them cooperated with public laboratories. Over three quarters of the interviewed 
firms cooperated with other biotechnology of pharmaceutical firms, and most of them collaborated 
with foreign private partners. 
 
In Latin American countries there are few new-to-the world innovators, as attested by the 
reduced number of patents. Only five companies had US, EPO or PCT patents. Yet in a few cases, 
these companies are conducting breakthrough research and development that may result in 
radical novelty. Most often than not, however, DBFs in Latin America are service providers 
linked to agricultural, pharmaceutical and environmental firms. Some of them are entirely or 
partially controlled by these companies to which they become captive service providers. 
Trademarks are indicators of some level of innovation (Mendonça et al, 2004). They play a key 
role in the marketing of innovation, as they allow potential and actual consumers to identify the 
product or service and its producer. In our sample, over 50% of the firms have requested 
trademarks, both for their products and their services, and in all the four countries. In addition, 
there is a strong correlation between having trademarks and patents: basically, almost all the 
companies with patents had trademarks, but two companies with trademarks had no patents. 
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4. Biotechnology in Latin America 
 
This study focuses on two of the largest countries in Latin America (Argentina and Brazil), one 
medium-size country (Chile) and a small country (Uruguay). These are among the countries with the 
highest human development index and the highest Gross Expenditure on R&D (GERD) as a 
percentage of Gross Domestic Product (GDP) in the region. Because biotechnology requires a skilled 
labour pool and strong expenditures on R&D, we considered that these countries were more likely 
than others to have undertaken some biotechnology service activity. 
 
4.1 Argentina’s biotechnology  
 
Argentina had a leading start in biotechnology in the region. In the early 1980s, it had a prompt entry 
in the science, with Dr Cesar Milstein, future Nobel Prize winner and discoverer of the methods to 
produce monoclonal antibodies. Argentina also had strong demand for both GMO from its large 
agricultural sector, and for biopharmaceutical drugs produced by a large generic pharmaceutical 
industry (Niosi et al, in press).  
 
Even if Argentina spends little funds in R&D in comparative terms, particularly when compared with 
South East Asia, there has been some progress in the recent years and the national statistical institute 
indicates that the Gross Expenditure on R&D (GERD) has moved from 0,41% in 2003 to 0,61% in 
2010. Researchers’ salaries were raised, non-reimbursable subsidies to R&D were increased and close 
to 1000 Argentinean researchers working abroad were repatriated. As a consequence, Argentina’s 
scientific publication has increased, even if the number of locally owned patents has barely 
augmented. 
 
 Main activities and locations 
 
The number of dedicated biotechnology firms (DBF) in Argentina, like in other Latin American 
countries, is a well-hidden secret. According to BIOTECSUR2, the MERCOSUR website for 
biotechnology, there are some 80 DBFs in Argentina, mostly dedicated to human and animal health 
and agricultural biotechnology. By contrast, Anlló et al (2011) found some 120 DBFs in Argentina for 
2008-9.  
 
Buenos Aires, the capital city, is the main location of these DBFs, followed by the Province of Buenos 
Aires; just three of them are located in the main cities of the Province of Santa Fe, Rosario and Santa 
Fe. Córdoba hosts only two. The geographical distribution of Argentinean DBFs mirrors the 
distribution of the Argentinean population, as well as its academic and industrial activity. 
 
Firm sizes and revenues 
Most DBFs are small firms with total employment between 5 and 10 employees. The average is 25 
employees, according to Anlló et al (2011). Multinational corporations (including one domestic MNC) 
dominate the agricultural biotechnology sector for the main crops (corn, soya beans, and sunflower), 
where few small DBFs still operate. One can still find small DBFs mainly in micro-propagation of 
cultures, the discovery of microbial inoculants and the development of GMO varieties in agricultural 
species that are not among the main crops. Only ten companies have more than 50 employees.  
 
According to Anlló et al (2011), Argentinean biotechnology firms produce some 1 billion US$ in sales 
annually, and export nearly 25% of what they produce. However, some of these firms may not be 
service companies; the OECD would classify them as biotechnology users operating in the 
pharmaceutical manufacturing industry, or trading companies, due to their main activity.  
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Government financial support 
In the early 1990s, Argentina created the National Agency for Scientific and Technical Promotion 
(ANCYPT), which started supporting a series of advanced science-based industries such as 
biotechnology. In 1993, Argentina established the FONTAR (Argentinean Technology Fund: the 
acronym is in Spanish).  
 
FONTAR distributes subsidies to dedicated biotechnology firms using both national and multinational 
funds (i.e. from the Inter-American Development Bank). Also, FONTAR attributes tax credits for 
R&D: Argentina spends annually some US$ 10 to 14 million for all industries in the entire country, 
but also uses funds transferred to it by the federal government or the public banks. Table 4a and 4b 
give some information about the funds distributed by FONTAR in biotechnology between 2000 and 
2004. Biotechnology received some USD 2 million a year, and the average R&D project received 
USD 57 000. 
 














Total amount in 
millions of 
USD 
R&D 114 6.5 1480 80.6 
Infrastructure 12 2.5 48 13.8 
Total  126 9 1528 94.4 
Biotechnology as a % of all 
sectors 
8.25% 9.7% 100% 100% 
Source: Biotecsur 
 
Table 4b: Argentina: Biotechnology R&D projects supported by FONTAR 
by area of application (2000-4) 
 
Area of application  Projects Amounts 
Number Percentage Millions USD Percentage 
Human health 43 38 4.5 67.6 
Animal health 34 30 1.3 19.5 
Food 16 14 0.5 7.7 
Vegetal health/inoculants 16 14 0.3 4 
Environment 4 4 0.1 1.3 




FONAPYME is a fund created in the 2000s to support small and medium-sized enterprises (SME) 
with loans for productive and R&D investment. In 2005 the loans for new firms amounted to about 
US$ 5000, and for existing firms up to 70% of the investment and US$ 60 000.  
 
Moreover, in 2006, the Central Bank supported soft credit lines (with interest rates around 50% that of 
private banks) for SMEs, with amounts up to US$ 3 million, and reimbursement periods up to 10 
years. Argentina, unlike countries like Brazil or Canada, has no national development bank.  
 
Also, in 2007 Argentina approved a National Biotechnology Plan, but the law was not implemented 
and thus no financial support was provided to Argentinean DBFs on the basis of this Plan. 
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On the whole, Argentina’s support for biotechnology is meagre not only compared to what Canada, 
the European Union, Japan, South Korea or the United States bring to the sector, but even compared to 
its giant neighbour Brazil.   
 
The public sector incubation of new technology-based firms is a new activity in Argentina. The largest 
and most research active university, the National University of Buenos Aires (UNBA), has a 
technology incubator called INCUBACEN, based on technologies developed at the Faculty of natural 
sciences. A new company, NEOINOCS, is developing microbial inoculants for plants. Another one, 
Biocodices, is working on bio-informatics. A third one, POLICLON, is developing biological reagents 
for animal health. Another incubator at the UNBA, INCUBAGRO, counts no new firm among its 
accomplishments3. The second Argentinean university, La Plata (UNLP), has a science and 
technology park where six new companies are located, including a biotechnology company, 




Argentina’s two main government laboratories – the National Institute for Agricultural Technology 
or INTA, and the National Institute for Industrial Technology or INTI – were founded in 1956. In 
2010, INTI inaugurated a new biotechnology laboratory with close to 30 employees. Its priority areas 
are the development of food enzymes to replace imported enzymes, and nanotechnology development 
for the controlled delivery of medicines.  
 
INTA hosts an Institute of Biotechnology, founded in 1989, and the Genetics Institute “Ewald Favret” 
(founded in 1992, on the basis of a previous Fitotechnical Institute), both close to the City of Buenos 
Aires. The Institute of Biotechnology hosts some 100 researchers and conducts research projects in the 
areas of bioinformatics, biomarkers, the genetics of plants resistant to different types of pathogens, as 
well as animal microbial infections. INTA collaborates with private firms as well as with universities 
and non-profit organizations. Its funding comes from appropriations from the national government, 
competitive national and international funds (including US NIH and European Union funds) and also 
from contracts offered by private firms. Because of the scientific training and affiliation of some of its 
staff, INTA does not have a culture of patenting its research results, and is keener on publishing 
articles and reports than on patenting. Patenting is more costly, takes more time and spends scarce 
resources needed to conduct research. Also, some of its results are probably not patentable. 
 
Besides these two large research centres, Argentina boasts an institution largely based on the Spanish 
CSIC, the French CNRS and the Italian CNRS: CONICET, the National Council for Scientific and 
Technical Research. Founded in 1958, it had a budget of US$400 million, and in 2011 it enrolled 
6,500 researchers and 2,500 technical personnel. It coordinates research conducted both in universities 
and at its own research institutes; many of its researchers are also university professors. It is 
impossible to know how many of them are working on biotechnology, as no such division of 
disciplines exists. 
 
 Government regulations 
 
Argentina has since the 1980s had a permissive attitude towards biotechnology, both in its agricultural 
and health applications. In the 1980s, Argentinean pharmaceutical firm Sidus was producing 
recombinant insulin. In the 1990s, Argentinean agriculturists were experimenting with transgenic 
crops. Regulation came at a leisurely pace. New plant varieties can be registered since 1987. Between 
1987 and 2006, some 903 varieties were registered in the National Register of Varieties, mostly from 
international companies, but also some from local ones. New genes in plant varieties can be patented 
since 1995. In a few years, both locally produced GMOs and imported ones were circulating in 
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Argentina. Argentina is today (2012) the third country in the world, after the USA and Brazil, in the 
area planted with transgenic crops. Most transgenic plants used in Argentina show resistance to 
herbicides and insects. 
 
In the area of health, Argentina only requires bioequivalence or comparability, based on the European 
Union model of 2005/6. In all cases the company trying to get a biological follow-on approved, must 
show through clinical and non-clinical trials, its comparability with a given originator (reference 
product).  
 
The companies we visited found that Government regulations are not expensive but they are slow. The 
authorization of a new-to-the-world human drug takes eight years, a biologic follow-on between 18 
and 24 months, and a new animal drug takes four years. Legislation on clinical essays seems another 
area of contention. There is no legislation on the number and quality of clinical essays required by an 
innovative drug, a situation that, according to them, hampers their entry into highly regulated markets 




Several Argentinean universities offer training and degrees in biotechnology. They include: 
 
- Graduate studies: National University of Buenos Aires – The Faculty of Agriculture offers 
a Master degree in biotechnology. A private university (UMAZA) in the Province of 
Mendoza also offers a master’s degree in bio-security. 
- Undergraduate: the National Universities of Litoral and Rosario (Province of Santa Fe) 
both offer undergraduate degrees in biotechnology. Also, the National Universities of La 
Plata, San Martin, Quilmes (province of Buenos Aires), as well as the National University 
of Tucumán (Province of Tucumán) offer similar degrees.  
Academic publication 
 
Five institutions concentrate over 60% of Argentinean publication in biotechnology: they are 
CONICET, the National University of Buenos Aires, the National University of La Plata, INTA and 
the National University of Córdoba (Table 5). Yet, a more complete picture would show that the 
number of biotechnology-activity research institutions increases every year.  
 
Table 5: Argentina: Main institutions producing biotechnology publications (1996-2011) 
 
Institution Number of articles % 
CONICET 1720 32 
National University of Buenos Aires 1024 19 
National University of La Plata 537 10 
INTA 318 6 
National University of Córdoba 232 4 
Five largest 3831 71 
All others 1511 29 
Total 5342 100 
Source: SCOPUS; figures produced by Science Metrix 
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Some relevant private service and hybrid DBF and their innovation  
 
Argentina has had for decades a fairly strong generic pharmaceutical industry, and a similarly strong 
agricultural industry. Both of them have invested in biotechnology and are large users of 
biotechnology services.  
 
Some of these users have created or acquired biotechnology R&D service firms. IND (located in 
Rosario, Santa Fe province) is a subsidiary of Bioceres, a private firm with over 200 shareholders, 
mostly innovative farmers. Founded in 2004, IND hosts some 150 researchers, working mostly on 
soya, sunflower and wheat seeds.  IND has obtained 27 patents, granted in Argentina, Australia and 
the USA, mostly on new or improved organisms. It conducts collaborative R&D with public 
institutions in Argentina (such as CONICET, INTA, INTI and research universities) and in 
neighbouring countries. It has also transferred technology to India. Its services include a platform for 
genomics and bioinformatics, the analysis of environmental impacts on microbial communities, RNA 
sequencing, and others5. 
 
Located in Buenos Aires and founded in 2006, AB is a successful private R&D product and service 
firm conducting innovative research on biosimilar drugs (follow-on biologics having lost their patent 
protection)6. AB produces twelve Active Pharmaceutical Ingredients (API) for biopharmaceutical 
drugs, as well as seven finished biosimilar drugs sold under the names of different Argentinean 
pharmaceutical firms. AMEGA is now conducting innovative R&D on five different monoclonal 
antibodies (MABs) and will build another plant to produce them. These products are exported to 
unregulated markets in Africa, Asia and Latin America. Thus, AB is a hybrid product and service 
company, which will soon conduct new services such as quality control and preclinical essays for 
other pharmaceutical firms. Hosting over 200 employees, AB is also growing fairly fast both in terms 
of employment and revenues.  
 
BC is an emerging bioinformatics firm being incubated at the National University of Buenos Aires. 
One of seven firms incubated by INCUBACEN, BC was recently launched by this incubator 
organization. The aim of the new company is to develop bio-informatics services using imported 
arrays and creating its own arrays. It will also customize R&D services and genomics diagnostics. It 
has already received an A$ 2 million grant (US$ 400 000) from ANCYPT7. Bio-informatics is 
insufficiently taught in Argentinean universities and its researchers are trained either abroad or on the 
job. 
 
Another emerging biotechnology R&D service firm is IM. A spin-off of the FIL, its goal is to produce 
several vaccines (for human and animal health) and license them out to pharmaceutical and veterinary 
companies. IM has received funds from the private equity market and is growing fast according to its 
R&D plan.  
 
PADN is a captive R&D service and product firm linked to the largest pharmaceutical Argentinean 
company. Founded in 2006, PADN was acquired by the pharmaceutical group in 2008. The private 
pharmaceutical company has 8000 employees across the world, and R&D activities in Argentina, 
China, India Italy and Spain. It manufactures products in Argentina, China, India, Italy, Spain and 
Uruguay. PADN is growing very fast, conducting collaborative research with Argentinean and foreign 
universities. Its funding comes from both its corporate owner, and national and international public 
agencies. In a few years, PADN will become a manufacturer of its own biopharmaceutical products, 
including first generation biosimilar drugs and its own MAB. It is important to note that its 
pharmaceutical owner is the only Argentinean group trying to produce new-to-the world 
biopharmaceutical drugs; PADN is part of that effort. 
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BE is a biotechnology firm focusing on plant biotechnology products and services. Founded in 2000, 
its employment and sales have experienced strong fluctuations, as the company moved from one area 
(large crops such as corn and soya) to more specialized products such as blueberries, capers and 
flowers, as well as functional food additives. The case illustrates the difficulties of plant biotechnology 
firms competing in key crop markets with multinational companies such as Monsanto, Pioneer or 
Syngenta; and in food additives with companies such as Natraceuticals.  
 
In short, five out of seven Argentinean companies in the study are growing in terms of both 
employment and revenues, either by adopting a service model, or a hybrid product-service one. Their 
productivity is also increasing. Two are not growing, and represent our less successful cases. 
 
Conclusion on Argentina 
 
Argentina has a strong agricultural and pharmaceutical industry able to demand bio-informatics, 
genomics and R&D services and products stemming from biotechnology. Its scientific institutions 
have long been the best in Latin America, and the only ones in the region that produced three Nobel 
prizes in science. However, some of its Latin American neighbors, particularly Brazil, are investing 
more than Argentina in biotechnology and may soon leave Argentina behind. Also, Argentina is 
notorious for its fast and unexpected changes in industrial policy: think of the 40-year lead Argentina 
had in aircraft, nuclear energy, and oil production and refining over other Latin American countries, 
and how this lead was suddenly lost. 
 
Lack of continuity in policy is reinforced by inadequate funds and idiosyncratic academic practices. 
Argentinean academic salaries are mediocre in a discipline that is developed by attracting the best and 
the brightest, research funds are increasing but are still reduced and industrial incentives for R&D are 
minimal compared not only with the United States and Western Europe, but also with emerging Asian 
countries such as China, India, Singapore, South Korea and Taiwan. Entire areas of biotechnology 
from bio-informatics to stem cell therapy are thus still underdeveloped. 
 
In the OECD countries, the venture capital industry has always developed thanks to smart government 
incentives such as national development banks or pension fund incentives (Gompers and Lerner, 
2004). Yet, the design and implementation of these polices, like all other innovation incentives, need 
careful crafting and continuous monitoring (Lerner, 2009). 
 
Argentina, as opposed to Brazil, has no national development bank that could launch a venture capital 
industry. The National Development Bank of Argentina was closed in 1976, a few years after it was 
founded. The private pension fund system, that helped both the United States and Canada to launch a 
venture capital industry, was nationalized in Argentina in 2008 in order to fund the federal 
government’s current expenditures.  
 
There are few signs of an implementation of the National Biotechnology Plan announced in 2007. 
Policy incentives appear scattered, and they lack continuity and solvency. Under these conditions, both 
dedicated biotechnology firms and industrial biotechnology users may have to count on themselves. 
 
Government financial support it is not very large, but companies got some funds from the Sector 
Funds, Banco de la Nación, but also from different programs run by the MINCYT. More serious is the 
fact that the national government is slowing its payment transfers to the provinces, thus rendering 
provincial hospitals unable to pay the drugs and services to domestic firms. 
 
4.2 Brazilian biotechnology 
 
As in many other industries (aircraft, automobile, nuclear, oil, etc.) Brazil had a later start compared to 
Argentina, but catches up and moves ahead fairly fast. Brazil GERD has increased from 0,85% of 
GDP in 2000 to 1,19% in 2011. Its public laboratories have a strong presence in agricultural and 
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human health biotechnology. And the number of its university graduates, particularly at the master and 
doctoral levels far outstrips Argentina. Its scientific publication in biotechnology is now in the top 15 
in the world. In addition, Brazil has created many technology-based firm incubators in its national 
universities and is also catching up in the number of biotechnology patents invented in the country. 
 
Main activities and locations 
 
Like in other Latin American countries, the precise number of biotechnology active firms in Brazil is 
unknown. The reason for this confusion is that three different types of firms are grouped together8: 
a) Dedicated biotechnology firms: companies producing R&D services, usually small and 
medium sized enterprises; 
b) Users of biotechnology products: these are usually large corporations operating in such 
areas as agriculture, environmental remediation services, food products, pharmaceuticals 
and other industries. 
c) Traditional biology services and products firms such as those discovering, reproducing 
and selling microorganisms that help plants to absorb nutrients and grow faster, or those 
that improve animal species and plants through hybridization. 
The interviews in Brazil showed that some of these companies (even some that boast the name 
“biotechnology”) are traditional biology firms and users of biotechnology. 
Thus, in 2009, according to the Biominas Foundation, there were 102 bioscience firms using 
biotechnology in Brazil (Biominas, 2010). Human health, agriculture, environment and energy, and 
animal health were the key application areas. The details of their activities are as follows (see Table 
6): 
Table 6: Brazilian biotechnology companies by main activity 
 
Area Activity N % 
Human health R&D for new therapies and vaccines 18  
 R&D for in vitro diagnostics 13  
 Contract research organizations 8 28% 
Agriculture Biological control of plagues 11  
 Seed improvement 9 19% 
Hybrid Molecular diagnostic services 10  
 R&D for several areas of application  5 15% 
Inputs Reagents 8 8% 
Environment Bioremediation and effluent treatment 8 8% 
Animal health R&D for recombinant vaccines 4  
 Animal genetic diagnostic services 4 8% 
Energy Improvement of plants to produce biodiesels 4 4% 
Total  102 100% 
Source: Biominas (2010): Estudo das empresas de biociências, Belo Horizonte. 
NB: there is no quality control on these figures; the number of DBFs may be lower. 
 
 
Another study, for 2011, found information about 145 users of biotechnology and dedicated 
biotechnology firms in Brazil, with a similar distribution of main areas of application (BR Biotec, 
2011). In this more recent study, the three main clusters were located in the sates of Sao Paulo 
(SP)(40.5%), Minas Gerais (MG)(24.5%) and Rio de Janeiro (RJ)(13.1%). Three states, according to 
Biominas, concentrated 78% of the biotechnology firms. In human health, SP, RJ and MG were the 
three main clusters. RJ was the main region for environment and energy, followed by SP. MG, SP and 
                                               
8 The North American Industrial Classification System (NAICS) has different codes for these industries. 
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RJ (together with Santa Catarina and other states) hosted agriculture DBFs. In sum, biotechnology was 
flourishing in the South of Brazil where the main universities and research centres are located. 
 
A more recent book suggests that there are some 40 to 60 dedicated biotechnology firms in Brazil, but 
also argues that SP, RJ and BH are the three main hubs for this activity (Uziel, 2012). 
 
As for users, Brazil, like Argentina, has a well-developed agricultural sector and a growing 
pharmaceutical sector, both of which can demand innovations from the domestic DBFs. In June 2012, 
Brazil announced the merger of four generic pharmaceutical companies into a new large firm called 
Bionovis, located in Sao Paulo. 
 
 Firm size and revenues 
 
Most DBFs and UBFs in Brazil are small firms. In 2011, 56% of them had revenues up to US$ 1.5 
million and around 85% of them had no more than 50 employees. Some 65% of them had 20 
employees or less. Some 86% of them imported products (reagents, equipment and/or services) but 
only 25% exported services or products. Half of the DBFs were or had been in business incubators, 
and almost 95% conducted collaborative research with universities or government laboratories, or 
shared their equipment (BR Biotec, 2011).  
 
 Government funding 
 
Since the late 1970s, the Brazilian government has supported research in biotechnology. The first 
funds aimed at the development of human resources and academic research were handled by 
Financiadora de Estudos e Projetos (FINEP), created in 1967, and the Conselho Nacional de 
Desenvolvimento Científico y Tecnológico (CNPQ), established in 1951. In 1999, the federal 
government created sector funds (FS) that linked science, technology and innovation under the aegis 
of FINEP, with a hint at industrial policy. Among these Sector Funds, two aimed directly at 
biotechnology: the Biotechnology Fund and the Health Fund. Other funds, aimed at Agro-Business, 
Energy, Infrastructure and other industries also occasionally supported biotechnology projects. These 
Funds handled over R$2481 million(US$1.2 billion) in 2010. The amount supporting biotechnology 
projects was not disclosed. In addition, FINEP also had a program of reimbursable loans for 
innovation (representing R$ 1 billion) and in 2006 it instituted a program of non-reimbursable grants, 
the value of which represented R$ 500 million in 2010. All in all, in 2010 FINEP handed over some 
US$ 2 billion to different projects; based on a conservative estimation, 10% of that amount went to 
biotechnology. 
 
Also, two new laws were approved to support innovation: the Innovation Law (L. 10973/2004) and the 
Goods Law (L. 11196/2007). The first allowed the state to support innovation by means of non-
reimbursable subsidies. The second put forward a tax credit for R&D incentive.   
 
Over 78% of Brazilian biotechnology firms used public finds in order to conduct R&D (BRBiotec 
2011). The main funds used came from FINEP, from other state agencies, from CNPQ, BNDES and 
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manufacturing activities. Today, FIOCRUZ hosts 7500 employees, working in 15 institutes across 
Brazil. Many of them work in biotechnology in one way or another, but Bio-Manguinhos (the 
Immunobiology Technology Institute) is key. Bio-Manguinhos is the largest producer of vaccines in 
Latin America. Its production includes vaccines against diphtheria, yellow fever, meningitis, measles, 
poliomyelitis, tetanus, and other infectious diseases, as well as reagents for AIDS, Chagas, rubella and 
other diseases. It is also located in Rio de Janeiro. 
 
Technology transfer between both EMBRAPA and FIOCRUZ and private firms is extensive, though 
no aggregate figures were available. Some publicized examples include the transfer of the technology 
used to produce a vaccine against Schistosomiasis (an illness caused by a parasite found in poor areas 
and affecting 200 million people in Brazil and elsewhere) to Alvos Biotecnologia, a Brazilian DBF, in 
2005.9 
 
 Government regulations 
 
Brazilian regulation of biotechnology products has started later than in Argentina. In agriculture, 
Brazil passed from a position of cautious resistance to transgenic crops to a warm approval of them 
starting in 1997. In a few years, Brazil became the second producer of GMO in the world. Again, like 
in Argentina, both local varieties and imported ones are circulating. EMBRAPA is producing most of 
the local transgenic varieties and distributing them mostly to poor farmers. The Ministry of 
Agriculture and Fisheries regulates the production and trade of transgenic crops. 
 
ANVISA regulates the approval of new drugs and other human health material. Brazil imports most of 
its biopharmaceutical drugs from the United States and the European Union. When it comes to 
biological follow-on products, like Argentina, Brazil has adopted the same regulations as Europe, 
namely that companies that want to introduce a biosimilar drug must prove their comparability with 
the most used drug in the country. Such regulation puts Argentinean, Chinese, Indian and other 
producers of biosimilar drugs at a disadvantage, because the drug that they have compared with in 
their own market, may not be the same used in Brazil. 
 
Some interviewed companies complained about the slow rhythm of approvals in Brazil and the 
incomplete character of legislation concerning different biotechnology products, particularly in the 




Brazil has developed a very extensive system of public and private universities. The public institutions 
are considered the best, particularly the federally funded universities like the Federal Universities of 
Sao Paulo, Rio de Janeiro, Rio Grande do Sul, Minas Gerais, Brasilia and Santa Catarina. Some state-
funded universities such as UNICAMP (the State University of Campinas, in Sao Paulo state) and 
UNESP (Sao Paulo State University) are also in the top ranks. Among the private universities, the 
Catholic Pontifical University of Sao Paulo (PUCSP) and the PUC of Rio de Janeiro (PUCRJ) are 
among the best ranked. All these universities are conducting teaching and research in biotechnology, 
as attested by their biotechnology incubation and publication activities. 
 
Brazilian universities – together with public laboratories - produce some of the knowledge used by 
domestic biotechnology firms. Firms also gather knowledge from foreign articles and patents, as well 
as scientific collaboration with foreign universities and public laboratories. 
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Most Brazilian DBFs were incubated in universities. Some thirteen incubators are operating in 
Brazilian universities and municipalities. The results of such incubation activity are very positive, if 
one judges by the large number of biotechnology firms housed in these organizations (see Table 7).  
 
Table 7: Brazil: Business Incubator or Technology Park 
 
Name Location  
(city and state) 
Area 
Bio-Rio (Pólo tecnológico 
de Rio de Janeiro) 
Rio de Janeiro 
(RJ) 
Created in 1988 as the first Latin American high-tech park. 
Located at the UFRJ, it counts over 40 life science firms10 
CDT  Brasilia          
(DF) 
Incubates companies in different high tech areas. Located 
at the University of Brasilia11 
CENTEV Viçosa  
(MG) 
Located at the University of Viçosa, hosts some 45 firms 
including 10 DBF12 
CIETEC Sao Paulo       
(SP) 
Founded in 1998, hosts some 150 companies including 18 
DBF. Located at the USP13 
HABITAT Belo Horizonte 
(MG) 
Founded in 1997 and specialized in biotechnology. Has 
incubated 20 DBF already in the market 
IE-CBIOT Porto Alegre 
(RS) 
Established in 1992, located at the UF Rio Grande do Sul, 
has incubated 7 biotechnology firms14 
INCAMP Campinas       
(SP) 
Associated with UNICAMP has 37 companies in the 
incubator, of which 7 in life sciences15 
INOVA Belo Horizonte 
(MG) 
Has 50 incubated companies, of which ten in 
biotechnology16 
PADETEC Fortaleza      
(CE) 
Located at the UF de Ceará, some 44 companies associated 
or graduated, including some DBFs17 
TECHNOPUC Porto Alegre   
(RS) 
Launched in 2003 in the Catholic University of Rio Grande 
do Sul, it hosts 77 companies; biotechnology is one of its 
areas18. 
POSITIVA Recife           
(PE) 
Located at the UF de Pernambuco, established in 2005, it 
hosts 5 DBFs 
PROSPECTA Botucatu        
(SP) 
Established in 2005, supported by UNESP, has 6 DBFs, in 
ag-bio and environment19 
SUPERA Riberâo Preto 
(SP) 
Focus on life sciences, established in 2003, has 10 resident 
firms in the incubator. Located at the USP campus in 
Riberâo Preto  
Sources: BRBiotec (2011) and web sites 
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Yet, almost without exception, their web sites are basically in Portuguese – a major difference 
between them and South East Asian universities and incubator portals, which aim to attract human 
capital and venture capital from the entire planet20. Brazilian incubators would benefit (as all Latin 
American science, technology and innovation institutions) from opening up to international ideas. 
Presenting themselves in the international language of investment, science and technology (English) 
would be a good practice to imitate. 
 
Publication shows a similar distribution. Over 40 educational institutions and several public research 
laboratories have had biotechnology articles in refereed journals since 1996. Yet only six of them 
concentrate more than 50% of their scientific publication in biotechnology according to SCOPUS 
databases (see Table 8).  
 
Table 8: Brazil: Biotechnology publication by research institution (1996-2011) 
 
Institution Total biotechnology 
articles 
% 
University of Sao Paulo 3826 22 
UNICAMP 1624 9 
State University of S. Paulo 1394 8 
Federal Univ. of Rio de Janeiro 1388 8 
EMBRAPA 1241 7 
Federal Univ. of Minas Gerais 993 6 
Subtotal 6 main institutions 10466 59 
Top ten institutions 13645 78 
Total Brazil 17591 100 
Source: SCOPUS, compilation by Science Metrix for Canada Research Chair  
on the management of Technology 
NB: There is some level of double counting as some researchers have multiple affiliations 
 
 
The University of Sao Paulo is Brazilian and Latin American top higher education institution. It was 
established in 1934 and enrols over 90,000 students. It also hosts Brazil’s largest incubator, and 
publishes more scientific articles than any other Latin American institution, including in 
biotechnology. The National University of Campinas (UNICAMP, also in the State of Sao Paulo) and 
the National University of Rio de Janeiro (UFRJ) follow in its trail – at certain distance. Among public 
research institutes, FIOCRUZ is number one in terms of scientific publication in biotechnology, 




Twelve firms were interviewed, but during the interviews it appeared that only eight of them were 
DBFs. The others were either manufacturing users or traditional biology firms.  
 
Location: These eight DBFs were located in Rio (four), Sao Paulo (three), Belo Horizonte (one) and 
Porto Alegre (one). In addition, the manager of the Bio-Rio incubator was also interviewed21. The Rio 
interviews were conducted personally and the others by phone, because of the short schedules 
allocated for the project. 
 
Applications: All these companies are active in R&D for human health biotechnology, including 
therapeutics, functional additives for food products, health cosmetics, diagnostics and other areas. One 
of these companies is also conducting R&D in animal health. All these companies – except one, which 
                                               
20 See the Shanghai incubator at http://www.tic.stn.sh.cn/en 
21 The names of the companies and the interviewees are kept confidential as agreed upon with the interviewees. 
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was acquired by a North American firm - are owned and controlled by Brazilian entrepreneurs. A 
majority of these DBFs were university spin-offs from such universities as the USP, UFRJ and 
UNICMP. Some of them were also incubated in their respective universities.  
 
Axis may be the most relevant firm in Rio de Janeiro. The group has adopted a hybrid product/service 
model, and is active in several lines of biotechnology products and services. The group includes a 
pharmaceutical company producing traditional generics (Sylvestre, founded in 1989), a stem cell 
databank service company providing stem cell storage and studying regenerative medicine 
(Cryopraxis, established in 2001), Cell Praxis (2007) and Pharma Praxis (2008), a recent 
biopharmaceutical company conducting R&D on biosimilar drugs that are not yet on the market.  
 
Another very relevant company is PN. Based in Sao Paulo, a spin-off from the University of Sao 
Paulo, it was founded in 2003, conducts R&D and produces products and services related to 
dermatology. PN is one of the few Brazilian biotechnology companies to have received funds from 
both domestic angel investors and BNDES. In 2012, the Toronto based biotechnology company 
Valeant took a minority position in the Brazilian DBF. 
 
BiOC was founded in 2004. Based in Belo Horizonte, State of Minas Gerais, it received local angel 
and venture capital. The company is an R&D service biotechnology firm working for both domestic 
and international clients, mostly in Canada, Europe and Latin America. 
 
Government Funding: The vast majority of these firms had received some financial help from 
FINEP, and one received a major venture capital amount from the BNDES. Most of these firms had 
requested funds from both FINEP and BNDES. Only two of them have had BNDES funds. Firms 
were critical about BNDES because the Bank devotes three quarters of its loans to large enterprises 
and just one quarter to SMEs. Also the firms criticized the fact that BNDES tends to refuse loans to 
support projects involving technological and/or commercial risk. FINEP was also criticized for its lack 
of continuity at supporting emerging technology-based firms: some programs were interrupted and 
resumed several years later, but biotechnology projects often span over several budgetary periods. 
Also, company executives in these DBFs underlined the fact that FINEP spends the vast majority of its 
funds on academic research (95%), and little (5%) on new technology-based firms. A majority of the 
funds gathered by seven of these eight companies came from the founders, family and friends. Just one 
of them received a major portion of its funds from BNDES. In Sao Paulo, the Foundation for support 
of Research at Sao Paulo State (FAPESP) was the main government-funding agency. Companies of 
that state were positive about the cost, and efficiency of FAPESP. 
 
Government regulations: one company complained about having spent 8 years to get a Brazilian 
patent. Government regulatory agencies (ANVISA for drugs), IBAMA (for environment) and Ministry 
of Agriculture (for genetically modified plants) are not knowable about these new products and 
services and are slow to proceed with the authorizations. Another company said that sometimes they 
have to teach ANVISA what to do to examine a new microorganism, and even more with stem cells. 
Another company underlined the fact that the Brazilian regulations (unlike the US law) do not allow 
registering a second use for the same or slightly modified drug. At least two companies mentioned the 
fact that regulatory norms are not clear in Brazil particularly when it comes to human health drugs. 
 
Government laboratories and universities: companies were unanimously positive about EMBRAPA 
and FIOCRUZ as having large portfolios of technologies, and a long experience of collaboration with 
DBFs. However, Brazilian universities are seen as engines of social mobility, not of economic 
development. Brazilian universities tend to block the modification of GMOS they have co-invented 
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Conclusion about Brazil 
 
Brazil has several advantages over all other Latin American nations, including its larger internal 
market, higher public expenditures on R&D, and more scientific publication on biotechnology than 
any other country in the region. Also, Brazil has a national development bank (BNDES), a type of 
institution no other country in the region has established. In addition, Brazil has developed a bio-fuel 
expertise unparalleled in the region, and it leads the region in the number of biotechnology incubators. 
However, in key areas of commercial biotechnology, Brazil seems to lag behind Argentina in many 
respects. 
 
In fact, even if the figures may not be entirely reliable, Brazil seems to have a smaller number of 
DBFs than Argentina. Also, the large size of Brazilian government laboratories (EMBRAPA and 
FIOCRUZ) may have discouraged private sector investment and entrepreneurship. In addition, the 
pharmaceutical industry of Brazil is not as advanced as that of Argentina, particularly in the 
development of biosimilar medicines. Thus, in Argentina there may be more private-sector demand for 
biotechnology R&D services than in Argentina. 
 
However, if historical trends over the last century offer some perspective on the future, Brazil has 
always started behind Argentina, whether on agricultural biotechnology, aerospace, or oil and gas 
exploration and refining, only to forge ahead several decades later. It is our impression that Brazil will 
catch up with Argentina in biotechnology products and services in the years to come. 
 
4.3. Chilean biotechnology 
 
Chilean biotechnology is fairly different from that of Argentina and Brazil. The main reason is that 
there are few users from agriculture and pharmaceutical industries. Unlike its largest neighbours, Chile 
has no large crops, a reduced animal stock, and a small generic pharmaceutical industry. In Chile, 
other sectors have the potential to fuel the development of biotechnology; they are: salmon farming, 
the fruit industry and the mining industry. Thus, the profile of Chilean biotechnology shows different 
specialties than those of Argentina and Brazil. However, the most distinguished biotechnologist in 
Latin America is Dr Pablo D. T. Valenzuela, former professor at the University of California, and co-
founder and Vice-president of Chiron Corporation. Valenzuela created the vaccine against hepatitis B, 
discovered the virus of hepatitis C, and developed a process to produce recombinant insulin using 
yeast. In 1997, Dr Valenzuela went back to Chile where he founded Fundación Ciencia para la Vida, 
and several new DBFs in human and animal health.  
 
 Number, location and application of biotechnology firms 
 
According to the association of Chilean biotechnology firms, ASEMBIO, there are ninety-three 
manufacturing users of biotechnology in that country, as well as sixty-one SMEs based in universities 
and twenty-two firms producing specialized services22. Chile also hosts some fifteen incubators 
prioritizing biotechnology, and ten academic technology transfer centres. Like in other countries, it is 
difficult to assess the accuracy of these estimations. According to this association, the key application 
sectors are mining, fishing (the salmon industry), fruits and sylviculture (plant pathologies and genetic 
markers for plant selection), and energy (mainly biofuel and biomass). The biotechnology sales of 
these firms would represent some 100 million USD. 
 
Santiago, the national capital is the main location of Chilean biotechnology firms, as well as the host 




                                               
22 http://www.asembio.cl/biotecnologia 
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 Government support 
 
Chile’s biotechnology policy focuses mainly on natural resources: forestry, mining, fruit, aquaculture, 
small animals and legumes are the main sectors. Issues include quality improvement, resistance to 
pathogens, biotic stress and gene selection. In mining, companies are interested in the development of 
bacteria that allow bioleaching, the separation of valuable minerals - in particular the recovery of 
copper - from other minerals.   
 
Between 1991 and 2001, the Chilean government supported 408 biotechnology R&D projects, for a 
total of 73.4 million USD23. Since then, public backing has been continuously growing, particularly 
after the creation of Innova Chile. 
 
Innova Chile (IC) is now the main fund supporting the development of Chilean biotechnology firms. 
IC was established in 2005 following the merger of two public funding agencies: FDI and FONTEC. 
Its missions are promoting innovation in private firms, stimulating innovative entrepreneurship and 
strengthening the national system of innovation. Biotechnology is one of its seven key areas of 
funding. The mechanisms through which support is provided are seed capital, business incubators, and 
the establishment of a network of angels. IC supports new technology-based firms with up to 
USD190.475 for three years.  
 
 Government regulations 
 
Chile forbids the introduction of transgenic crops for both human and animal consumption, but allows 
their production for exports as seeds. This regulation has made Chile an important producer and 
exporter of GMO in international markets. Also, Chile forbids the liberation of living transgenic 
animals in domestic waters. Yet there is some R&D taking place on the genomics of Chilean plants 
and animals for purposes of finding cures to different plagues and diseases such as those that affect 
Chilean salmon fisheries. 
 
In terms of biopharmaceutical drugs, Chile allows their patenting and imports most of its products 




Four Chilean universities dominate the landscape in biotechnology publication: Universidad de Chile, 
Pontificia Universidad Católica de Chile (PUCC), Universidad de Concepción, and Pontificia 
Universidad Católica de Valparaíso (PUCV).Table 9 gives some details about their publication 
activities. 
 
Table 9: Chile: academic publication in biotechnology, main universities 1996-2011 
 
 
Twenty other universities have some publications on biotechnology, as well as several university 
hospitals and foundations. 
                                               
23Chile: Comisión nacional para el desarrollo de la biotecnología (CNDB), 2003: p. 8. 
University Total biotechnology  articles % 
Universidad de Chile 636 31 
Universidad de Concepción 316 15 
PUCC 306 15 
PUCV 202 10 
All other institutions 596 29 
Total 2056 100 
 





Two main laboratories conduct research on biotechnology and publish their results in refereed 
journals: the National Agricultural Institute (INIA) and the Milenio Institute of Fundamental and 
Applied Biology (MIFAB).  
 
INIA was founded in 1964 as a private organization reporting to the Chilean Department of 
Agriculture, that funds some 44% of its revenues, the remaining coming from the sale of services and 
seeds. In 2010, INIA hosted 600 employees, working in several stations across the country24. INIA 
conducts biotechnology research aiming at the genetic improvement of legumes and fruits. It also aims 
at preserving the genetic heritage of the country and transmitting its research results to universities, 
DBFs and other research centres. INIA is not working on genetic engineering but rather on gene 
identification of useful plants and plant pathogens. INIA appears in 9th rank in terms of scientific 
publication on biotechnology in Chile. 
 
The Milenio Institute (MIFAB), founded in 1999, focuses its work on human pathology, more 
precisely on the molecular basis of cell regulation and cell functions. Among its research projects, 
some focus on cancer, diabetes and obesity. MIFAB also works on the pathogens of salmon. It hosts 
eleven senior researchers, including Dr Valenzuela, its director. However, neither Milenio nor INIA 
have received any US patents yet25. MIFAB’s main researchers are active in one or the other of two 
Chilean universities (Andrés Bello and PUCC) as well as the Foundation for life sciences. MIFAB 
appears in 11th rank in Chile in terms of scientific publication. 
 
 Dedicated biotechnology firms 
 
Four dedicated biotechnology firms were interviewed in Chile, all of them in Santiago. Three of them 
were active in human health and one in mining biotechnology. The mining DBF is the result of a 
consortium of a large domestic copper company and a foreign multinational corporation; its goal is to 
develop bioleaching processes for the copper industry. This biotechnology company, founded in 2002, 
has already been granted seven US patents, since 2009. It sells its services to its two major 
shareholders and to financial supporters. 
 
By far the largest Chilean company, Grupo Bios26 operates in human and animal health R&D. It was 
founded in 2008 by Dr Pablo Valenzuela, and already has 130 employees. It has developed molecules 
for diagnostics kits for several human and animal diseases. It is now trying to export products 
(molecules and kits) to the United States. It is offering custom-made MAB services. Its funding 
initially came from public funds, and now comes from sales in the domestic market. This company has 
also licensed its molecules to a large multinational pharmaceutical corporation. However, the firm has 
no patents, either in the country or in other OECD nations. 
 
A smaller DBF is operating in the same areas as the one above: human and animal health. Mostly 
supported by government funds, its growth has been less spectacular than that of Grupo Bios. Yet it 
exports to the United States and its productivity is also showing strong growth.  
 
Companies had some complaints about regulations in Chile. Speed and cost were not issues. There is 
no regulation on biotechnology diagnostics in the country, and this fact represents an obstacle to 
exports to other countries. 
 
                                               
24 www.inia.cl 
25 www.mifab.cl 
26 Grupo Bios (2011): Servicio de anticuerpos monoclonales murinos a pedido, Santiago, 6 pages (www.grupobios.cl). 
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These DBFs had experienced productivity growth of over ten percent in the last five years, besides 
increasing total employment by between 14% and 50%. In Chile, supported by a developmental state, 
growth is taking place, at least for the largest DBFs. 
 
4.4 Biotechnology in Uruguay 
 
Compared to its larger neighbours, Uruguay has a less significant human capital pool, a more reduced 
internal market and smaller government funds to support the domestic development of a set of costly 
and complex technologies. Yet, the country has managed to introduce biotechnology services and 
products through small and medium-sized enterprises. Because its economy and government policy is 
similar to that of Argentina, there are striking similarities in the distribution of biotechnology among 
biotechnology firms in both countries.  
 
Number, location and application of biotechnology firms 
 
Like in most developing countries, particularly in Latin America, there are no official statistics on the 
number of dedicated biotechnology firms. The Biotecsur website27 publishes a list of 13 biotechnology 
Uruguayan companies. However, a more detailed analysis of this list finds that most of them are either 
pharmaceutical corporations (such as Clausen), producers of recombinant animal health vaccines (i.e. 
Santa Elena) or companies producing inoculants for edible plants. In fact, the latter are considered 
biotechnology users, manufacturing specific lines of products. Once the list was analyzed, one is left 
with only four dedicated biotechnology firms producing R&D services. 
 
 Government support 
 
In 2012, Uruguay published a national Biotechnology Plan28, but like in Argentina, no practical 
implementation or funding followed. Yet, the Plan contains some figures and forecasts about what 
biotechnology was in 2012 and what it could aspire to be in 2020. The training of human resources, 
creation of an adequate regulatory framework for biotechnology, and a better coupling of industry and 
academia were among the goals for the next decade. The Plan did not publish any figures about what 
the government might invest in the next decade. Uruguay, like Argentina, has no National 
Development Bank.  
 
In Uruguay, government support is more reduced than in Argentina, Brazil or Chile. Support for 
innovation is confined to the National Agency for Research and Innovation (ANII is the Spanish 
acronym). ANII uses mostly external funds, provided by the national government, the Banco de la 
República Oriental del Uruguay (BROU), or external agencies such as the Inter-American 
Development Bank, UNESCO, World Bank, the UN Development Fund, the European Commission 
and others. 
 
ANII is a private organisation under government control. It is the key actor in the implementation of 
the National Strategic Plan for Science, Technology and Innovation. ANII supports innovation in 
private companies through different schemes. It also distributes grants to local students for graduate 
studies in the United States. Its total annual budget through government appropriations in 2011 was 
about US$ 26 million (plus US$ 3 million in funds coming from foreign sources). Even if the funds 
are modest (US$ 0.75 per inhabitant) they have grown exponentially from US$ 8.5 million in 2008, to 
US$ 18.5 million (2009), and US$ 21 million in 2010.  
 
Several programs support biotechnology firms. The reader may be astonished by the modest amounts 
involved. 
 
                                               
27 www.biotecsur.org 
28 Uruguay ( 2012): Gabinete productivo, Plan Sectorial de biotecnología, Montevideo, 48 pages. 
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(a) The Sector Funds for Agriculture, Energy, and Health could finance biotechnology projects. The 
2011 ANII Annual Operative Plan reports that 6 projects were supported: two in energy for US$ 
238,000 (almost US$ 120 000 per project) and four in agriculture for US$ 359 000 (or US$ 90 000 per 
project) . But the Plan does not specify whether these were biotechnology projects29.  
 
(b) The “Clemente Estable” Fund for fundamental research, which may also support biotechnology 
research, was forecasting total disbursement in 2012 for all disciplines of about 1.7 million USD for 
77 projects, or US$ 22 000 per project.  
 
(c) In 2010, the “Maria Viñas” Fund for applied research had approved 65 projects for all disciplines 
for a total of 1 225 million, or 18 800 USD per project. 
 
A program aimed at promoting alliances among universities, private innovative firms and government 
laboratories in the life sciences was implemented in the late 2010. But according to a well-known 
Uruguayan expert, the program was not successful for the simple reason that few companies conduct 
R&D in Uruguay, and the handful of government laboratories and research universities in the country 
are seldom involved in biotechnology research. 
 
Uruguay has no tax credit for R&D, but it has a tax credit for investment, the average amount granted 
being around US$ 80 000. Some biotechnology companies interviewed have used this investment 
incentive. None had received funds from the sector or from the other R&D funds. 
 
Uruguay has not promoted the development of a venture capital industry; there are no incentives for 





Uruguay has two government laboratories that mirror Argentina’s INTA and INTI. They are the 
National Institute for Agricultural Research (INIA),and the Uruguayan Technology Laboratory 
(LATU). Neither of them has biotechnology research among its missions. At a given moment, INIA 
obtained some funds (US$ 50 000 to 100 000) for agricultural biotechnology, but had no personnel to 
conduct that research. Similarly, for a short period of time, LATU obtained some funds to acquire 
biotechnology equipment but had no budgets to hire the specialised personnel required to use them, or 




Uruguay has developed a National System of Researchers (NSR), giving bonuses to the most 
productive academics in their system. But the NSR has a clear preference for fundamental research 
and articles, not for applied research and patents. Such a bias, according to a responsible person from 
the Department of Industry, makes links between university and industry difficult. 
 
Two universities in Uruguay teach and conduct some research on biotechnology. The largest is the 
Universidad de la República (UDELAR). Founded in 1949, there is some research and teaching at the 
Faculties of Sciences, Medicine and Agriculture. Between 1996 and 2011, Uruguayan scholars 
published a total of 356 scientific articles. UDELAR was responsible for 61% of them, followed by 
the Ministry of Education, the Louis Pasteur Institute (a private non-profit research centre) and INIA. 
No other institution had biotechnology publications. 
 
The Universidad ORT, founded as a pre-university private college in 1942, became a university in 
1985. In 2010, ORT created the first and only university degree in biotechnology in the country, under 
                                               
29 ANII (2011): Plan Operativo Anual 2011, Montevideo. 
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the supervision of Mr Carlos Sanguinetti, M. Sc., one of the most distinguished Uruguayan 
biotechnologists. This 4-year undergraduate program teaches molecular biology, agricultural 
biotechnology, bioinformatics, bioprocesses and other relevant disciplines. After the first 3 years, the 
program grants a degree of Technician in biotechnology.  
 
The Pasteur Institute in Montevideo was founded in 2004 and inaugurated in 2007, through an 
agreement with the French Pasteur Institute. It focuses on three main areas: protein chemistry, 
molecular biology and structural biology, linked by bioinformatics. The Institute will conduct research 
and train local and regional human resources in biotechnology. The French government supported the 
new Institute through a € 5 million grant and the Uruguayan government contributed € 1 million. Its 
annual budget will be US$ 650 000. In 2007 an international committee selected three competitive 
research projects, which started their work the same year. Two other research teams were added the 
following years.30 
 
Scientific publication in biotechnology is modest but it exists, particularly at the Universidad de la 
República (UDELAR), where most of it takes place (Table 10) 
 
Table 10: Uruguay: academic publication in biotechnology, main institutions 1996-2011 
 
University Total biotechnology Articles % 
UDELAR 217 63 
Department of Education 39 11 
INIA 16 5 
I. Pasteur 16 5 
Others  58 16 





Uruguay allows patenting of both transgenic crops and biopharmaceutical products. Uruguay imports 
all of these products mostly from original innovating countries. A government supported study on the 
prices of biopharmaceutical drugs published in Colombia (Zapata and Steiner, 2012) showed that 
among the Latin American countries included in the study, Uruguay was systematically the one that 
paid the highest prices, followed by Brazil. Argentina was systematically the one where the prices 
were the lowest. The domestic competition in Argentina, against the total absence of competition in 
Uruguay and the reduced competition in Brazil were the main factors explaining very substantial 
differences in process in these countries. 
 
 Dedicated biotechnology firms 
 
Informed respondents suggested that there are no more than five or six biotechnology firms in 
Uruguay. For the purposes of this project, the PI interviewed a total of six firms, but only two of them 
were dedicated biotechnology firms, the others being in fact manufacturers of different products 
(biotechnology users). 
 
ATG was founded in 2001 as a dedicated R&D services biotechnology firm. The largest domestically 
controlled pharmaceutical company in Uruguay acquired ATG,a spin-off from the UDELAR that has 
developed expertise in diagnostics for different illnesses including Chagas, HIV and cancer. Like 
several companies already mentioned in Argentina, ATG has become a captive R&D service provider 
                                               
30 http://www.pasteur.edu.uy/institution/overview 
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for a biotechnology user. Under the umbrella of the larger firm, ATG is growing, both in terms of 
employment and revenues. And like its Argentinean counterparts, its productivity is also rising. 
 
Gen, established in 1993, is a private biotechnology pure service company. Its specialty is the analysis 
of DNA. It started conducting service tests for herpes, moved to paternity tests and the creation of 
DNA banks, and now is focused primarily on gene identification in order to understand the genetic 
basis of the effectiveness of some drugs marketed by multinational corporations. In addition, it 
conducts gene identification for security services. Finally, it has diversified into gene identification of 
large cattle. The company exports services towards different Latin American countries, and conducts 
R&D in Argentina and Uruguay. Its employment, revenues and its productivity are growing fast.  
 
LSE, not included in the statistics, is probably the largest biotechnology user in Uruguay for animal 
health. The company has some 80 products in the market, 60% of which are biological vaccines 
mostly for large animals. The company is 56 years old, and has recently passed an alliance with 
French Virbac, in order to gain complementary knowledge on a different set of veterinary products. 
Virbac also provided capital and access to new markets. LSE was a spin-off of UDELAR. Its business 
model is hybrid product/service, where products have the lead. LSE conducts research with UDELAR, 
INIA, LATU, ORT and the Pasteur Institute in Montevideo. It also collaborates with large national 
universities in Brazil and Argentina.   
 
The companies that have envisaged producing follow-on biologics found that the complete absence of 
regulations on these products, made their investment highly risky.  
 
Conclusion on Uruguay 
 
Uruguay has a more reduced potential to develop science-and technology-based service SMEs. Yet 
some companies are growing thanks to the entrepreneurial effort of their creators, and focusing on the 
two major applications that are available to them: animal and human health. Like other Latin 
American countries, Uruguay invests little on public and academic R&D, and thus it forces companies 
to rely exclusively on revenues they generate. In a sector where technical change is very fast, and 
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5. Conclusion and policy implications  
 
In biotechnology innovation takes essentially form through R&D. all the 22 companies interviewed 
were conducting R&D even if it was with reduced amounts of funds due to scanty government 
incentives for private-sector R&D. Almost of all them were practicing “open innovation”, 
collaborating with domestic research universities and public laboratories, and most often with foreign 
biotechnology and pharmaceutical firms in order to gain complementary knowledge. Over one third of 
the companies had patents, and five of them had been granted US, European and/or PCT patents, 
showing that some new-to-the world R&D is taking place in the region. This new-to-the-world 
innovation is most probably in the area of drug delivery, than in the composition of the drugs 
themselves. The use of trademarks in the largest of these biotechnology service firms and 
biotechnology users shows that some level of novelty is being created. 
 
However, imitative innovation (copying) products invented elsewhere is the norm in Latin America’s 
biotechnology. In two of our selected countries, Argentina and Brazil, domestic generic 
pharmaceutical companies and public government laboratories are moving towards the production of 
biological copies of existing biopharmaceuticals that are losing patent protection in the United States 
and Europe. In Chile, a start-up DBF is moving in the same direction: imitative innovation of 
biopharmaceutical drugs. 
 
In the area of organizational innovation, imitation is also the rule: open, collaborative innovation and 
the creation of captive biotechnology firms is not a new-to the world organizational innovation; it is 
the way many large pharmaceutical companies based in Europe, Japan and North America are 
incorporating biotechnology. 
 
Biotechnology services companies are being created in all the four countries, and some of them show 
increasing employment, revenues and productivity, despite reduced government support for advanced 
academic and public-sector R&D, limited domestic markets and small human capital pools, 
particularly at the level of star scientists. Pure service biotechnology companies are more easily 
established in the region than product companies. These service companies require less start-up 
capital, smaller investments in R&D, and are often able to develop a stream of revenues fairly rapidly.  
 
In Argentina and Uruguay, several large pharmaceutical corporations have acquired biotechnology 
R&D service companies; in Argentina, a group of agricultural firms has also followed this path to 
internalize biotechnology R&D services. In Chile, mining companies have established their own 
captive R&D service provider. In the same country, the presence of a word-class star scientist is 
allowing Chile to propose highly sophisticated biotechnology health services to the world. But the 
R&D service model is not the only one existing in the region. Other biotechnology services, such as 
bioinformatics, gene identification and others, even more specialized, such as stem cell bank services, 
are also part of the biotechnology landscape in the region.  
 
 
  35 
 
Figure 3 summarizes the innovation activities of the firms and their impacts, both in terms of visible 







User surveys are one important method of assessing the quality of public innovation policy incentives 
and regulations (Georghiou and Roessner, 2000).Policymakers have helped to understand the rationale 
of the programs. Yet, our survey of biotechnology companies, even if it is not statistically 
representative, points to some deficiencies in the regulatory and innovation policy environment.  
 
Competition policy: if Argentina’s health system and consumer were paying often lower prices for 
biotechnology drugs than those based in Brazil and Uruguay, this is because Argentina has taken some 
care of its pharmaceutical industry, and the industry has learned to live under little support, macro-
economic turmoil and a permissive regulation. The combination of stronger public funds for 
innovation and a soft regulation may probably improve the situation in at least Argentina, and 
probably in Brazil. In sum, bringing local producers to the competitive arena, both at home and 
abroad, may produce welfare benefits to the region’s health systems and consumers.  
 
Venture capital: Following the experience of more advanced OECD countries, Latin American 
countries should be interested in building the fundamentals of a solid venture capital industry, either 
through their national development banks (Brazil) or the private-sector pension fund system, by 
allowing them to invest a small percentage of their assets in high-technology DBFs. Other paths are 
also available: countries such as Canada and Israel have invited well-known venture capital firms to 
create local subsidiaries in order to accelerate learning in this most sophisticated financial industry. 
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Academic research and training: biotechnology services are based on advanced human capital 
(Zucker et al, 1998).  In order to accelerate the incorporation of highly skilled human capital in the 
region, several paths are possible. Brazil and Chile have relied on generous fellowships allowing 
students to increase their skills abroad. This practice is valuable but not very cost effective: nearly half 
of the students do not complete their careers, and among those that do complete their advanced 
degrees, half of them tend to remain in the country where they have trained (NSF, 2010). Countries 
like the United States and Canada offer accelerated immigration procedures to successful students 
having completed their graduate degrees in these countries, a practice that tends to reduce the 
effectiveness of the Brazilian and Chilean training policies. Singapore has taken a faster and more 
cost-effective route: it imports star scientists from across the globe. These scientists bring not only 
badly needed skills, but also research funds from national and international foundations such as the US 
National Science Foundation, the British Wellcome Trust, the Gates Foundation, the Volkswagen 
Foundation and hundreds of others in North America and Europe. In addition, these star scientists train 
local students in the most advanced technologies. Thus, the developing country that imports such 
intellectual human capital is less likely to lose its newly skilled graduates who are trained at home. 
Yet, this practice requires a system of private and public sector chairs open to global competition and 
adjudicated by international committees, a practice that is common in North America but not in Latin 
America, where endogamy in recruitment is often the norm in academia31. The salaries of these star 
scientists should be internationally competitive. A major change in mindsets is required in Latin 
American academia. 
 
Procurement innovation policy: government hospitals and other public agencies can help the 
development of biotechnology service SMEs in such applications as gene identification, 
bioinformatics and stem cell banks by outsourcing them to the private domestic sector instead of 
developing them in-house. Such a practice may create a fertile ground for new companies to grow and 
eventually export such services to other countries.  
 
Approval and regulations: almost unanimously, companies suggested that approval and registry of 
biotechnology products and services was fairly long and complex. Most important, they found that 
public employees in charge of these regulatory activities were sometimes unable to perform their task 
because of the very sophisticated and knowledge-intensive character of these activities. A more 
through investigation about these potential obstacles may be necessary. 
 
Statistical offices: the region is seriously lagging in the quantity and quality of its statistics, and 
particularly but not exclusively concerning R&D, science and technology. No country in the region 
knows exactly how many dedicated biotechnology firms it hosts, or what the public and private R&D 
expenditure in biotechnologies is32.  
 
In summary, the policy incentive supply in science-based industries, particularly in the area of 
biotechnology services, is badly underdeveloped in the region. It would benefit from being revamped 
in order to diversify the economies of a region that is increasingly dependent on natural resources, and 
to support the development of high-technology services. A more complete survey of the users of these 
policy incentives and regulations could collect useful ideas on how to increase the policy tools in Latin 
America. More micro-evidence is needed on the impact of these incentives that, even if they are 
modest in comparative international terms, cost hundreds of millions of dollars to the four countries 
involved in this survey. 
                                               
31 For the definition of star scientists in biotechnology and their impact on industry, see Zucker et al (1998) and Niosi and 
Queenton (2010). Star scientists are people who have invented at least five biotechnology patents, and authored at least 50 
publications in refereed journals. Under this definition, Dr Pablo Valenzuela the inventor in over 30 US granted 
biotechnology patents, and may well be the only biotechnology star scientist in the region. 
32Another staggering evidence of quality deficiency came to light in 2009, when Chile was admitted into the OECD, and 
under the quality control of this international organization its R&D statistics suffered a dramatic reassessment. We may 
wonder what would occur if Argentina, Brazil, or Uruguay were admitted to the OECD and their statistical data came 
under quality control. 
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Country City Organization Type of organization 
Argentina Buenos Aires Biocientifica  DBF 
  Biocodices DBF 
  BioExt DBF 
  Gema Biotech  DBF 
  Incubacen Academic incubator 
  Inmunova DBF 
  PharmADN  DBF 
  INTI Government laboratory 
  MINCYT Government department 
 Castelar INTA Government laboratory 
 Rosario INDEAR DBF 
Brazil Belo Horisonte Biocancer DBF 
 Florianopolis LBE Biotech Not a DBF 
  WAB Biotech Not a DBF 
 Porto Alegre FK Biotecnologia DBF 
 Rio de Janeiro BioRio Academic incubator 
  Axis/Cryopraxis DBF 
  ENgene DBF 
  GCTbio DBF 
  StrategoBio DBF 
  Usinaverde Not a DBF 
  EMBRAPA Government laboratory 
  FIOCRUZ Government laboratory 
 Sao Paulo Inventa Pharma DBF 
  Pelenova DBF 
  Recepta Pharma DBF 
  FAPESP Government department 
Chile Santiago BioSigma DBF 
  BioSonda DBF 
  Grupo Bios DBF 
  Venturelab DBF 
  Innova Chile  Government department 
  INIA Government laboratory 
Uruguay Montevideo ATGen DBF 
  Calister Not a DBF 
  Genia DBF 
  Lab. Santa Elena Biotechnology user 
  Lage Not a DBF 
  Ministry of Industry Government department 
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Annex 2:  Cuestionario en Biotecnología 
 
 
Propósito del estudio. 
El estudio se centra en las características y las actividades de las compañías que utilizan o desarrollan 
la biotecnología como parte de su actividad.  
 
¿Quién debe completar este cuestionario?.  
Un directivo que conozca detalladamente la compañía, puede completar este cuestionario.  
 
Confidencialidad. 
Los datos serán tratados con estricta confidencialidad. Estos se utilizarán para los fines estadísticos y 
se divulgarán, solamente, en forma agregada. 
 

















Si las utiliza corriente, usted las utiliza para Número de 

















    
Ingeniería y 



















    
Nanobiotecnología Si…. 
No…. 





    




    
Sección 1: Uso de la Biotecnologías (utilice la siguiente la tabla) 
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Sección 2: Recursos Humanos en Biotecnología 
 
2. Número de empleados en Biotecnología. 
a)   ¿Cuántos empleados empleó su compañía en este país el 2011? ...............................  
b) ¿Cuántos empleados tenían responsabilidades relacionadas a la biotecnología en el 2011? 
......................  
c) Empleados con responsabilidades en biotecnología a tiempo completo......................... 
 
Posición 
Número a tiempo completo 
Dirección/investigación científicas................................................................... 
Técnicos ........................................................................................................... 
Asuntos reguladores/clínicos ........................................................................... 
Producción ....................................................................................................... 
Finanzas/comercialización/desarrollo de negocios ......................................... 
Gerencia administrativa ................................................................................... 
Otro, especifique por favor: ............................................................................. 
Empleados totales con responsabilidades en biotecnología, a tiempo completo..................... 
 
d) Empleados con responsabilidades en biotecnología a tiempo parcial ( por horas) 
Para cada grupo enumerado abajo, indique cuántos son empleados con responsabilidades a tiempo 
parcial (por horas) en biotecnología (menos el de 50% de su tiempo pasa en actividades relacionadas a 
la biotecnología). Si un empleado ejecuta más de una tarea, diga su responsabilidad primaria. Cuente a 
cada persona solamente una vez. Diga por favor el nivel  de empleo típico para 2011 en los 
equivalentes a tiempo completo (FTE). 
 
Posición 
Número a tiempo completo 
Dirección/investigación científicas............................................................ 
Técnicos .................................................................................................... 
Asuntos reguladores/clínicos .................................................................... 
Producción ................................................................................................ 
Finanzas/comercialización/desarrollo de negocios ...................................  
Gerencia administrativa ............................................................................ 
Otro, especifique por favor: ....................................................................... 
Empleados totales con responsabilidades a tiempo completo en biotecnología ..................... 
 
e) Número Total de empleados en biotecnología.  
Total de empleados a tiempo completo y tiempo parcial relacionados a actividades de 
biotecnología……………………………………………………………………………………. 
 
f) Evolución del empleo (ETC) y de los ingresos ($ miles) en biotecnología del 2007 al 2011 
 
 2007 2008 2009 2010 2011 
Empleo       
ingresos      
 
 
3. Practicas de Personal y reclutamiento. 
 
a) ¿Su compañía tiene cargos relacionados a la biotecnología sin completar (ocupar)?  
No: Vaya a preguntar 3 b)  
 
  43 
 
Sí: En la tabla abajo indique el número de cargos sin completar por categoría:  
Número de cargos sin completar 
Dirección científica/investigación....................................................... 
Técnicos ............................................................................................... 
Asuntos reguladores/clínicos ............................................................... 
Producción ........................................................................................... 
Finanzas/comercialización/desarrollo de negocios ............................. 
Gerencia administrativa ....................................................................... 
Otro, especifique por favor: ................................................................. 
 
b) ¿Su compañía tiene un programa formal de entrenamiento y desarrollo para el personal 




c) ¿Su compañía intento reclutar a cualquier empleado en biotecnología el 2011? 
No… Vaya a la pregunta 5 
Si … tuvo éxito ? 
No…va a la pregunta 3d  
Sí… cuántos contrato usted? 
 
d) ¿Usted intentó contratar a personal en biotecnología que residía fuera del país el 2011?  
No…  
Si…en la tabla abajo indique el número de personal en biotecnología empleado de cada región. 
Región Repatriación Contratación 
Internacional 
Total 
Estados Unidos    
Canadá    
Europa    
China    
India    
Asia (otro de China o 
India) 
   
Otro (por favor 
especifique) 
   
Total de empleados 
contratados del 
exterior 





4. a) Alguien del personal de biotecnología dejo la compañía el 2011? 
No…  Vaya a la pregunta 6 
Si… ¿Cuantos? 
 








5. ¿Cuántos años tiene la compañía de establecida? ........................ 
 
6. ¿Su compañía es pública? 
No…  Vaya a la pregunta 8 
Si… ¿Que ano fue la oferta pública inicial (IPO)? 
 
7. a) ¿Su compañía se ha fusionado con otra compañía? 
No…  Vaya a la pregunta 8 
Si… En qué año ocurre la fusión? 
 
b) ¿Cuáles fueron las razones de la fusión? 
……………………………………………………………………………………………………… 
 
8. a) ¿Su compañía es una firma nacional?  
No…  Vaya a la pregunta 10 
Si… 
 
b) ¿Su compañía tiene sucursales fuera de este país? 
No… 
Si… ¿Su compañía realiza I+D fuera de este país? 
No… Si… 
 
9. Su compañía es un spin-off? (Un spin-off se define como una nueva compañía creada para 
comercializar desarrollo tecnológico en universidades, laboratorios públicos u otras compañías) 
No…  Vaya a la pregunta  10 
Yes… Su compañía es un spin-off de: 
 Universidad/ Hospital 
 Otra compañía biotecnológica  
 compañía no biotecnológica 
 Agencia o laboratorio gubernamental 









Esta sección investiga acerca del desarrollo de los nuevos productos y de los procesos de la 
biotecnología de su compañía. 
 
10. a) ¿Tiene usted procesos/productos en el Mercado que requieran el uso de biotecnología?  
Si…    (Por favor nombre los tres procesos o productos mas importantes  bajo su desarrollo)  
No…  
 
b) ¿Su compañía desarrolla actualmente productos que requieran el uso de biotecnología? 
Si…     No… 
Sección 3 – Historia de la compañía 
Sección 4: Productos Innovativos en Biotecnología  
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c) ¿Su compañía desarrolla actualmente procesos que requieran el uso de biotecnología?  
Si…     No… 
 
d) ¿Considera a la biotecnología central en su compañía para sus actividades o estrategias? 
Si…     No… 
 
11. a) En la siguiente tabla, por favor indique el Número de productos o procesos en biotecnología que 
su compañía tiene actualmente para cada etapa de desarrollo en el sector de salud humana. Si es “0” 









clínica I  
Fase 








Diagnósticos       
Terapias       
Drogas       
 
b) En la siguiente tabla, por cada sector listado por favor indique el Número de productos o procesos 
de biotecnología que su compañía tiene actualmente por cada etapa de desarrollo. Si es “0” (cero) por 






















    
Biotecnología 
animal 
    
Agricultura no 
alimentaria para uso 
industrial 
    
Agricultura no 
alimentaria para uso 
medico 
    
Recursos naturales 
Energía     
Minería     
Productos forestales     
Ambiente 
Aire     
Agua     
Suelo     
Acuicultura 
Sanidad de peces,     
 







    
Terapia génica     
Procesos alimenticios 




    
Otros (especifique)     
 
 
Sección 5: Regulación de Productos Biotecnológicos  
 
12. a) En el 2011, ¿tenía usted productos/procesos de biotecnología en alguna etapa de I+D, pero 
no aun en el mercado?  
No…. Vaya a la pregunta 13 
Si… Vaya a la pregunta 12 b 
 
b) De los productos o de los procesos en biotecnología  que su compañía tenia en etapas de 
investigación y desarrollo (no aun en el mercado) en 2011, ¿cuántos requerían la evaluación y/o 
la aprobación formal de autoridades reguladoras nacionales? Número………. 
 
c) El 2010, para su principal producto en biotecnología, ¿cuál es la duración total de su proceso 
regulador hasta la fecha (en meses)? 
……………………………………………………………………………………………………. 
 
d) ¿Cuál era su gasto el año pasado en I+D? 
…………………………………………………………………………………………………….. 
 
e) ¿Cual era su gasto el año pasado en regulación? 
……………………………………………………………………………………………………. 
 
13. ¿Ha Usted tenido problemas en los procesos regulatorios, tales como:  
Costos     Si….. No….. 
Rapidez   Si….. No….. 
Normas    Si….. No….. 
Otros      Si….. No….. 
 
14. a) ¿Hizo su compañía contratos fuera de las actividades relacionadas a la biotecnología en el 
2011?  
 
Organización Número de contratos  
CRO (Contrato con organización de investigación)  
CMO (Contrato con industria)  
Universidad/hospital  
Laboratorios gubernamentales  
Otras compañías de biotecnología  
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b) ¿Proporcionó su compañía servicio de contrato a otras compañías u organizaciones? No…. 
Vaya a la pregunta 15 




Organización Número de contratos 
Otras compañías de biotecnología  
Compañía farmacéutica  
Otra forma que biotecnología o farmacéutica  
Laboratorios gubernamentales  
Universidad/hospital  
Otra, por favor especifique  
Total  
 
Acuerdos de colaboración. 
 
Los arreglos cooperativos y de colaboración implican la participación activa en proyectos 
entre su compañía y otras compañías u organizaciones para desarrollar y/o continuar el trabajo 
en nuevos o procesos significativamente mejorados en biotecnología, productos y/o servicios. El 
trabajo de contratación externa  no se mira como colaboración. 
 
15. a) Su compañía estuvo implicada en acuerdos de cooperación/colaboración relacionados a la  
biotecnología con otras compañías u organizaciones en 2010? (Incluya por favor ambos casos  
dentro y fuera del país) 
No…  Vaya a la pregunta 16 




















Conducir I+D      
Asuntos 
reguladores 
     
Acceso a otras 
patentes 
     
Producción/fa
bricación  
     
Acceso 
mercados  
     




     
Acceso a otras 
técnicas del 
conocimiento 
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b) ¿En 2010, su compañía estuvo implicada en acuerdos de cooperación/colaboración 
relacionados a la biotecnología con otras empresas u organizaciones extranjeras (situadas fuera 
del país)? 
No…  Vaya a la pregunta  16 
Si… En la siguiente tabla, marque los acuerdos de cooperación/colaboración por cada tipo de socio 
y su ubicación geográfica:  
 
Tipo de socio USA Europa Canadá China India Otro 
Compañía biotecnología       
Compañía farmacéutica       
Otra compañía que biotecnología y 
farmacéutica 
      
Laboratorio gubernamentales       
Universidad/hospital       
Otro, por favor especifique 
 
      
 
c) Clasifique los siguientes propósitos para formar acuerdos de colaboración/cooperación con un socio 
extranjero(localizado al exterior). Liste los tres más importantes 
 
 
Propósito de acuerdo Listado 
Conducir I+D  
Asuntos reguladores  
Acceso a otras patentes  
Producción/fabricación  
Acceso a mercados  
Acceso a capital  
Acceso a propiedad intelectual  




16 a) Su compañía solicito u obtuvo patentes relacionadas a la biotecnología o tiene patentes 
pendientes para sus invenciones? 
No…  Vaya a la pregunta 16 b  
Si… Cuantas? Indique la distribución de patentes relacionadas a la biotecnología y patentes 
pendientes que su compañía tiene en la oficina de patentes:  
 
 Nacional USPTO Europea Otro 
Existencia de 
patentes 
    
Patentes 
pendientes 
    
Patentes 
expiradas 
    
 
 
16 b) Su compañía tiene marca comercial relacionada a la biotecnología? 
No…   Vaya a la pregunta17 
Si…  Cuantas?....................................... 
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17. a) Su compañía asigna o autoriza derechos de Propiedad Intelectual (PI)  relacionado a la 
biotecnología con otras compañías? 
No…   Vaya a la pregunta 17 b 
Si…  Por cada tipo de instrumento de PI listado abajo, por favor indique el número de derechos de 
PI concedido según el país.  
 












Acuerdo de licencia     
Asignación de patente     
Acuerdo de transferencia 
tecnológica 
    
Otra, por favor especifique     
 
17 b) ¿Su compañía ha adquirido derecho de propiedad intelectual relacionado a la 
biotecnología de otra compañía?  
No…   Vaya a la pregunta 20 
Si…  Por cada tipo de Instrumento de PI listado abajo, por favor indique el Número de derechos de  
PI obtenido por el país?  
 












Acuerdo de licencia     
Asignación de patente     
Acuerdo de transferencia 
tecnológica 
    





18. Por favor complete la siguiente tabla. Si la información no esta disponible, por favor proporcione 
una estimación cuidadosa en US$. 
 




   
Porcentaje de ingreso  
biotecnología 
   
Gasto total I+D  
 
  
Porcentaje de gasto en 
I+D en biotecnología 






Sección 7- Característica de la compañía y perfil financiero 
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Actividades de financiamiento 
 
19. a) ¿Su compañía intentó reunir capital para los fines de la biotecnología en el 2011? 
 
No…¿Porque no?.................................................................................................................. 
 Vaya a la pregunta 20 
Si…  Porque intentó usted reunir el capital? (por favor, revise todas las respuestas que se aplican). 
 Propósitos de I+D  
 Producción 
 Comercialización de productos 
 Gastos reguladores clínicos 
 
19 b) ¿Fue exitoso en reunir el capital?  
 
 No… Vaya a la pregunta 19d 
Si… Cuanto capital reunió usted el 2011? …………. 
 
19 c) ¿Alcanzo usted su objetivo? 
No… Vaya a la pregunta  19 d 
Si … Vaya a la pregunta 19 e 
 
19 d) ¿Que razones hicieron que el prestamista/proveedor limitara los fondos o rechazara el 




19 e) ¿Que Fuentes proporcionaron el financiamiento?  
 
Fuente % 
Capital de riesgo nacional  
Capital de riesgo US  
Capital de riesgo europeo  
Capital de riesgo de otros países  
Capital otros (ej. Bancos)  
Inversionistas ángeles, familia, amigos  
Gobierno  
Colocación privada  
Oferta Privada Inicial (IPO)  
Oferta Privada secundaria (SPO)  




20. Solicito su compañía créditos fiscales para I+D? 










  51 
 
21. ¿Exportó su compañía productos de biotecnología en el 2011? 
No… Vaya a la pregunta 22 







Otros (por favor, especifique) 
 
22. a) Importo su compañía productos de biotecnología el 2011? 
No… Vaya a la pregunta 23 







Otros (por favor, especifique) 
 
b) ¿En 2010, cuáles eran los usos principales finales previstos de los productos biotecnológicos 
importados por su compañía? (Indique por favor “sí” o “no").  
Uso final.  
Reventa como producto final.  
Uso como producto intermediario o materia prima en:  
Siembra  y plantación.   
Utilización comida/alimentos.  
Biología veterinaria.  
Droga/farmacia.  
Otro por favor, especifique. 
  
 
  52 
 
 
Sección 8: Uso de estrategia en el 2011 
 
23. Indique por favor la importancia de cada una de las siguientes estrategias de  su compañía 
en el desempeño del 2011, por “sí” o “no”.  
 
Conocimiento de estrategias de desarrollo  
          Sí  No 
Captura y uso del conocimiento obtenidos de otras fuentes  
de la industria tales como asociaciones industriales, competidores,  
clientes y surtidores. 
 
Captura y uso del conocimiento obtenido de instituciones de  
Investigación pública incluyendo universidades y laboratorios 
Gubernamentales. 
 
Desarrollo de nuevos conocimientos a través de acuerdos de  
Colaboración con otras compañías u organizaciones. 
 
Uso y actualización de base de información científica y base de 
Datos. 
 
Desarrollo de políticas y prácticas de la firma en la PI. 
 
Desarrollar o alentar el aumento de la educación del personal. 
 
Conducir una intervención de PI para asegurar la protección de los 
Productos y procesos en todas las etapas de desarrollo. 
 
Usar la PI como signo de competitividad 
 
Estrategias de negocios 
 
Aumenta el tamaño de la compañía a través de la adquisición o  
fusión de una empresa adjunta. 
 
Reducción de operaciones de la compañía. 
 
Promover productos o servicios de otras compañías basados 
en descubrimientos interinos o aumento de I+D para generar flujo 
de ingresos 
 
Ingresar productos o procesos de ensayo/adaptados  para  
aumentar el ingreso al mercado. 
 
Comienza nuevas investigaciones y desarrollo de proyectos. 
 
Expandirse a los mercados extranjeros  
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Protocolo entrevistas con funcionarios públicos en programas accesibles a empresas de 
biotecnología 
1. ¿Cuál es el presupuesto anual que su organismo dedica a la biotecnología? 
2. ¿Por medio de qué trámites se distribuye esa ayuda? 
3. ¿Cuál es el objetivo de la ayuda (ejemplo: I+D, obtención de patentes, control de calidad, 
contratación de personal altamente calificado, compra de equipo…) 
4. ¿Qué tipo de empresa recibe esos incentivos (grande, pequeña o mediana, sector, región…)? 
5. ¿Qué otros programas similares existen a nivel nacional, provincial o municipal? 
6. ¿Cuántas empresas recibieron esa ayuda en los últimos tres años? Por favor especifique año 
por año. 
7. ¿Cuál es el monto promedio de la ayuda, por empresa? 
8. ¿Cómo se compara ese programa con otros programas de incentivos dentro del país? 
9. ¿Cómo se compara ese programa con otros similares en América Latina? En otros países? 
10. ¿Cuánto personal cuenta esta oficina? 
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